BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Teraoka S, Fujimoto D, Morimoto T, Kawachi H, Ito M, Sato Y, Nagata K, Nakagawa A, Otsuka K, Uehara K, Imai Y, Ishida K, Fukuoka J, Tomii K. Early Immune-Related Adverse Events and Association with Outcome in Advanced Non-Small Cell Lung Cancer Patients Treated with Nivolumab: A Prospective Cohort Study. J Thorac Oncol 2017;12:1798-805. [PMID: 28939128 DOI: 10.1016/j.jtho.2017.08.022] [Cited by in Crossref: 238] [Cited by in F6Publishing: 260] [Article Influence: 39.7] [Reference Citation Analysis]
Number Citing Articles
1 Cortijo-Cascajares S, Cercós-Lletí AC, Ortiz-Pérez S, Caro-Teller JM, Ferrari-Piquero JM. Analysis of immune-mediated reactions in patients with non-small cell lung cancer treated with nivolumab and its association with effectiveness. J Oncol Pharm Pract 2023;29:290-8. [PMID: 34907812 DOI: 10.1177/10781552211067429] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Zhou Y, Chen H, Tang L, Feng Y, Tao Y, Huang L, Lou N, Shi Y. Association of immune-related adverse events and efficacy in advanced non-small-cell lung cancer: a systematic review and meta-analysis. Immunotherapy 2023. [PMID: 36710655 DOI: 10.2217/imt-2022-0028] [Reference Citation Analysis]
3 Zhang Y, Zhu T, Nie R, Lu L, Xiang Z, Xie D, Luo R, Cai M. Association between Early Immune-Related Adverse Events and Survival in Patients Treated with PD-1/PD-L1 Inhibitors. JCM 2023;12:736. [DOI: 10.3390/jcm12030736] [Reference Citation Analysis]
4 Yang F, Shay C, Abousaud M, Tang C, Li Y, Qin Z, Saba NF, Teng Y. Patterns of toxicity burden for FDA-approved immune checkpoint inhibitors in the United States. J Exp Clin Cancer Res 2023;42:4. [PMID: 36600271 DOI: 10.1186/s13046-022-02568-y] [Reference Citation Analysis]
5 Zhang J, Wang S, Zhou Z, Lei C, Yu H, Zeng C, Xia X, Qiao G, Shi Q. Unpleasant symptoms of immunotherapy for people with lung cancer: A mixed-method study. Int J Nurs Stud 2022;139:104430. [PMID: 36638590 DOI: 10.1016/j.ijnurstu.2022.104430] [Reference Citation Analysis]
6 Fujimoto A, Kotake Y, Hisamatsu D, Ookubo N, Yabuuchi Y, Kamimura G, Kai T, Kozono A, Ootsu T, Suzuki H, Matsuo K, Kuwahara K, Oiwane Y, Nagata Y, Tanimoto K, Sato E, Suenaga M, Uehara T, Ikari A, Endo S, Hiraki Y, Kawamata Y. Risk factors indicating immune-related adverse events with combination chemotherapy with immune checkpoint inhibitors and platinum agents in patients with non-small cell lung cancer: A multicenter retrospective study.. [DOI: 10.21203/rs.3.rs-2355931/v1] [Reference Citation Analysis]
7 Tan Q, Liu L, Huang Y, Dong X, Chen L. Case report: A rare case of neutropenia caused by pembrolizumab in squamous lung cancer and literature review. Front Oncol 2022;12:973421. [PMID: 36505877 DOI: 10.3389/fonc.2022.973421] [Reference Citation Analysis]
8 Goto Y, Yoh K, Kato T, Hosomi Y, Usui K, Fukui T, Hirano K, Tanaka H, Taguri M, Kunitoh H. Observational study to predict the efficacy and optimal duration of nivolumab treatment in patients with previously treated advanced or recurrent non-small cell lung cancer. Jpn J Clin Oncol 2023;53:153-60. [PMID: 36300307 DOI: 10.1093/jjco/hyac159] [Reference Citation Analysis]
9 Iwahori K, Uenami T, Yano Y, Ueda T, Tone M, Naito Y, Suga Y, Fukushima K, Shiroyama T, Miyake K, Koyama S, Hirata H, Nagatomo I, Kida H, Mori M, Takeda Y, Kumanogoh A, Wada H. Peripheral T cell cytotoxicity predicts the efficacy of anti-PD-1 therapy for advanced non-small cell lung cancer patients. Sci Rep 2022;12:17461. [PMID: 36261600 DOI: 10.1038/s41598-022-22356-0] [Reference Citation Analysis]
10 Kapoor A, Noronha V, Patil VM, Joshi A, Menon N, Kumar A, Mahajan A, Janu A, Kumar R, Prabhash K. Association of Immune-Related Adverse Effects and Survival in Solid Tumor Patients Treated with PD1 Inhibitors. South Asian J Cancer. [DOI: 10.1055/s-0041-1740243] [Reference Citation Analysis]
11 Chen J, Wen Y, Chu X, Liu Y, Su C. Pulmonary adverse events associated with hypertension in non-small cell lung cancer patients receiving PD-1/PD-L1 inhibitors. Front Pharmacol 2022;13:944342. [DOI: 10.3389/fphar.2022.944342] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Ma Y, Ma X, Wang J, Wu S, Wang J, Cao B. Absolute eosinophil count may be an optimal peripheral blood marker to identify the risk of immune-related adverse events in advanced malignant tumors treated with PD-1/PD-L1 inhibitors: a retrospective analysis. World J Surg Oncol 2022;20:242. [PMID: 35897018 DOI: 10.1186/s12957-022-02695-y] [Reference Citation Analysis]
13 Higashiyama RI, Horinouchi H, Kuchiba A, Matsumoto Y, Murakami S, Goto Y, Kanda S, Fujiwara Y, Yamamoto N, Ohe Y. Non-specific symptoms as a prodrome of immune-related adverse events in patients with non-small cell lung cancer receiving nivolumab: a consecutive analysis of 200 patients. J Cancer Res Clin Oncol 2022. [PMID: 35900471 DOI: 10.1007/s00432-022-04205-9] [Reference Citation Analysis]
14 Bredin P, Naidoo J. The gut microbiome, immune check point inhibition and immune-related adverse events in non-small cell lung cancer. Cancer Metastasis Rev 2022. [PMID: 35876944 DOI: 10.1007/s10555-022-10039-1] [Reference Citation Analysis]
15 Gannichida A, Nakazawa Y, Kageyama A, Utsumi H, Kuwano K, Kawakubo T. Necessity of neutrophil-to-lymphocyte ratio monitoring for hypothyroidism using nivolumab in patients with cancer. World J Clin Oncol 2022; 13(7): 641-651 [DOI: 10.5306/wjco.v13.i7.641] [Reference Citation Analysis]
16 Chye A, Allen I, Barnet M, Burnett DL. Insights Into the Host Contribution of Endocrine Associated Immune-Related Adverse Events to Immune Checkpoint Inhibition Therapy. Front Oncol 2022;12:894015. [DOI: 10.3389/fonc.2022.894015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Ortega-Franco A, Hodgson C, Raja H, Carter M, Lindsay C, Hughes S, Cove-Smith L, Taylor P, Summers Y, Blackhall F, Califano R. Real-World Data on Pembrolizumab for Pretreated Non-Small-Cell Lung Cancer: Clinical Outcome and Relevance of the Lung Immune Prognostic Index. Target Oncol 2022. [PMID: 35781861 DOI: 10.1007/s11523-022-00889-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
18 Chen Y, Zhuang L, Zhang D, Du X, Sheng L, Cui D. Thyroid Dysfunction as a Predictive Indicator in Camrelizumab of Advanced Esophageal Squamous Cell Carcinoma. Journal of Immunology Research 2022;2022:1-8. [DOI: 10.1155/2022/4015897] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Zhou J, Wong AH, Wang H, Tan F, Chen X, Jin S, He S, Shen G, Wang Y, Frey B, Fietkau R, Hecht M, Ma H, Gaipl US. Elucidation of the Application of Blood Test Biomarkers to Predict Immune-Related Adverse Events in Atezolizumab-Treated NSCLC Patients Using Machine Learning Methods. Front Immunol 2022;13:862752. [DOI: 10.3389/fimmu.2022.862752] [Reference Citation Analysis]
20 Takahashi Y, Nagaya T, Iwaya Y, Okamura T, Hirayama A, Iwaya M, Uehara T, Umemura T. CD8(+) Lymphocyte Infiltration Is a Specific Feature of Colitis Induced by Immune Checkpoint Inhibitors. Dig Dis Sci 2022. [PMID: 35748996 DOI: 10.1007/s10620-022-07598-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Kanabar SS, Tiwari A, Soran V, Balendran P, Price M, Turner AM. Impact of PD1 and PDL1 immunotherapy on non-small cell lung cancer outcomes: a systematic review. Thorax 2022:thoraxjnl-2020-215614. [PMID: 35688624 DOI: 10.1136/thoraxjnl-2020-215614] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
22 Chieng JHL, Htet ZW, Zhao JJ, Tai ES, Tay SH, Huang Y, Wong A, Yang SP. Clinical Presentation of Immune-Related Endocrine Adverse Events during Immune Checkpoint Inhibitor Treatment. Cancers 2022;14:2687. [DOI: 10.3390/cancers14112687] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
23 Takada K, Shimokawa M, Takamori S, Shimamatsu S, Hirai F, Tagawa T, Okamoto T, Hamatake M, Tsuchiya-Kawano Y, Otsubo K, Inoue K, Yoneshima Y, Tanaka K, Okamoto I, Nakanishi Y, Mori M. A propensity score-matched analysis of the impact of statin therapy on the outcomes of patients with non-small-cell lung cancer receiving anti-PD-1 monotherapy: a multicenter retrospective study. BMC Cancer 2022;22:503. [PMID: 35524214 DOI: 10.1186/s12885-022-09385-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
24 Yoneda T, Sone T, Koba H, Shibata K, Suzuki J, Tani M, Nishitsuji M, Nishi K, Kobayashi T, Shirasaki H, Araya T, Kita T, Kase K, Yamamura K, Terada N, Nishikawa S, Tambo Y, Kimura H, Kasahara K. Long-term survival of patients with non-small cell lung cancer treated with immune checkpoint inhibitor monotherapy in real-world settings. Clinical Lung Cancer 2022. [DOI: 10.1016/j.cllc.2022.03.008] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
25 Zhong X, Ying J, Liao H, Shen L, Pan Y. Association of thyroid function abnormality and prognosis in non-small-cell lung cancer patients treated with PD-1 inhibitors. Future Oncol 2022;18:2289-300. [PMID: 35440175 DOI: 10.2217/fon-2021-1537] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Murao K, Mori Y, Takahashi Y, Ishikawa T, Asai Y, Kobayashi T, Ikeda K, Kuronuma K, Magara K, Fujita H, Hirohashi Y, Takasawa A, Chiba H. Simultaneous Pseudoprogression and an Immune-related Adverse Event of Pulmonary Pleomorphic Carcinoma after Combined Therapy with Cytotoxic Anticancer Agents and Immune Checkpoint Inhibitor. Intern Med 2022. [PMID: 35400698 DOI: 10.2169/internalmedicine.8916-21] [Reference Citation Analysis]
27 Valencia Soto CM, Villacañas Palomares MV, Garcia-Avello Fernández-Cueto A, Barbadillo Villanueva S, Martínez Callejo V, Ochagavía Sufrategui M, Muñoz Cacho P, Valero Domínguez M. Predictive value of immune-related adverse events during pembrolizumab treatment in non-small cell lung cancer. Eur J Hosp Pharm 2022:ejhpharm-2021-003038. [PMID: 35383033 DOI: 10.1136/ejhpharm-2021-003038] [Reference Citation Analysis]
28 Ye Z, Zheng S, Chen J, Zhang Y, Yang S, Hong Y, Yang H, Xuan Z, Zhao Q. Can Immune-related adverse events serve as clinical biomarkers of PD-1/PD-L1 inhibitor efficacy in Pan-Cancer Patients? Int Immunopharmacol 2022;108:108738. [PMID: 35395468 DOI: 10.1016/j.intimp.2022.108738] [Reference Citation Analysis]
29 Asano Y, Yamamoto N, Demura S, Hayashi K, Takeuchi A, Kato S, Miwa S, Igarashi K, Higuchi T, Yonezawa H, Araki Y, Morinaga S, Saito S, Sone T, Kasahara K, Tsuchiya H. The Therapeutic Effect and Clinical Outcome of Immune Checkpoint Inhibitors on Bone Metastasis in Advanced Non-Small-Cell Lung Cancer. Front Oncol 2022;12:871675. [DOI: 10.3389/fonc.2022.871675] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
30 Serino M, Freitas C, Martins M, Ferreira P, Cardoso C, Veiga F, Santos V, Araújo D, Novais-bastos H, Magalhães A, Queiroga H, Fernandes G, Hespanhol V. Predictors of immune-related adverse events and outcomes in patients with NSCLC treated with immune-checkpoint inhibitors. Pulmonology 2022. [DOI: 10.1016/j.pulmoe.2022.03.003] [Reference Citation Analysis]
31 Baker ML, Yamamoto Y, Perazella MA, Dizman N, Shirali AC, Hafez N, Weinstein J, Simonov M, Testani JM, Kluger HM, Cantley LG, Parikh CR, Wilson FP, Moledina DG. Mortality after acute kidney injury and acute interstitial nephritis in patients prescribed immune checkpoint inhibitor therapy. J Immunother Cancer 2022;10. [PMID: 35354588 DOI: 10.1136/jitc-2021-004421] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
32 Yin J, Wen M, Cheng J, Hu L, Yang L, Chang X, Zhou Z, Li H, Liu Y, Li J. A Patient With Failed Liver Transplantation After the Use of PD-1 Blockade Combined With Lenvaxen. Front Med (Lausanne) 2022;9:712466. [PMID: 35265635 DOI: 10.3389/fmed.2022.712466] [Reference Citation Analysis]
33 Takada K, Shimokawa M, Takamori S, Shimamatsu S, Hirai F, Ono Y, Tagawa T, Okamoto T, Hamatake M, Okamoto I, Mori M. The clinical impact of concomitant medication use on the outcome of postoperative recurrent non-small-cell lung cancer in patients receiving immune checkpoint inhibitors. PLoS One 2022;17:e0263247. [PMID: 35130287 DOI: 10.1371/journal.pone.0263247] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
34 Adda L, Batteux B, Saidak Z, Poulet C, Arnault J, Chauffert B, Séjourné A. Effets indésirables rhumatologiques associés aux inhibiteurs de points de contrôle immunitaire : impact sur la survie globale. Revue du Rhumatisme 2022;89:168-175. [DOI: 10.1016/j.rhum.2021.10.564] [Reference Citation Analysis]
35 Kalfeist L, Galland L, Ledys F, Ghiringhelli F, Limagne E, Ladoire S. Impact of Glucocorticoid Use in Oncology in the Immunotherapy Era. Cells 2022;11:770. [PMID: 35269392 DOI: 10.3390/cells11050770] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
36 Passaro A, Leighl N, Blackhall F, Popat S, Kerr K, Ahn MJ, Arcila ME, Arrieta O, Planchard D, de Marinis F, Dingemans AM, Dziadziuszko R, Faivre-Finn C, Feldman J, Felip E, Curigliano G, Herbst R, Jänne PA, John T, Mitsudomi T, Mok T, Normanno N, Paz-Ares L, Ramalingam S, Sequist L, Vansteenkiste J, Wistuba II, Wolf J, Wu YL, Yang SR, Yang JCH, Yatabe Y, Pentheroudakis G, Peters S. ESMO expert consensus statements on the management of EGFR mutant Non-Small Cell Lung Cancer. Ann Oncol 2022:S0923-7534(22)00112-0. [PMID: 35176458 DOI: 10.1016/j.annonc.2022.02.003] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 14.0] [Reference Citation Analysis]
37 Argnani L, Casadei B, Pelusi C, Lo Preiato V, Pagotto U, Bertoni F, Zinzani PL. Immune-related adverse events in the treatment of non-Hodgkin lymphoma with immune checkpoint inhibitors. Sci Rep 2022;12:1753. [PMID: 35110658 DOI: 10.1038/s41598-022-05861-0] [Reference Citation Analysis]
38 Abdihamid O, Omar A, Rugambwa T. Defining the correlation between immune-checkpoint inhibitors-related adverse events and clinical outcomes: a narrative review. Ecancermedicalscience 2021;15:1314. [PMID: 35047065 DOI: 10.3332/ecancer.2021.1314] [Reference Citation Analysis]
39 Jing Y, Yang J, Johnson DB, Moslehi JJ, Han L. Harnessing big data to characterize immune-related adverse events. Nat Rev Clin Oncol 2022. [PMID: 35039679 DOI: 10.1038/s41571-021-00597-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
40 Hamada K, Yoshimura K, Oshinomi K, Hirasawa Y, Ariizumi H, Ohkuma R, Shida M, Kubota Y, Matsui H, Ishiguro T, Sambe T, Ishida H, Horiike A, Wada S, Iwamoto S, Uchida N, Ogawa Y, Kobayashi S, Tsunoda T. A case of bronchial asthma as an immune-related adverse event of pembrolizumab treatment for bladder cancer: A case report. Medicine (Baltimore) 2022;101:e28339. [PMID: 35029177 DOI: 10.1097/MD.0000000000028339] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
41 Takahara Y, Tanaka T, Ishige Y, Shionoya I, Yamamura K, Sakuma T, Nishiki K, Nakase K, Nojiri M, Kato R, Shinomiya S, Fujimoto Y, Oikawa T, Mizuno S. Efficacy and predictors of rechallenge with immune checkpoint inhibitors in non-small cell lung cancer. Thorac Cancer 2022. [PMID: 34989146 DOI: 10.1111/1759-7714.14309] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
42 Sano A, Sohda M, Nakazawa N, Ubukata Y, Kuriyama K, Kimura A, Kogure N, Hosaka H, Naganuma A, Sekiguchi M, Saito K, Ogata K, Sakai M, Ogawa H, Shirabe K, Saeki H. Clinical features as potential prognostic factors in patients treated with nivolumab for highly pretreated metastatic gastric cancer: a multicenter retrospective study. BMC Cancer 2022;22:22. [PMID: 34980017 DOI: 10.1186/s12885-021-09118-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
43 Rengarajan M, Faje A. Anti-neoplastic Immunomodulatory Treatments and the Pituitary. Pituitary Disorders throughout the Life Cycle 2022. [DOI: 10.1007/978-3-030-99918-6_25] [Reference Citation Analysis]
44 Yang F, Wang JF, Wang Y, Liu B, Molina JR. Comparative Analysis of Predictive Biomarkers for PD-1/PD-L1 Inhibitors in Cancers: Developments and Challenges. Cancers (Basel) 2021;14:109. [PMID: 35008273 DOI: 10.3390/cancers14010109] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
45 Xu S, Lai R, Zhao Q, Zhao P, Zhao R, Guo Z. Correlation Between Immune-Related Adverse Events and Prognosis in Hepatocellular Carcinoma Patients Treated With Immune Checkpoint Inhibitors. Front Immunol 2021;12:794099. [PMID: 34950153 DOI: 10.3389/fimmu.2021.794099] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
46 Takada K, Takamori S, Shimokawa M, Toyokawa G, Shimamatsu S, Hirai F, Tagawa T, Okamoto T, Hamatake M, Tsuchiya-Kawano Y, Otsubo K, Inoue K, Yoneshima Y, Tanaka K, Okamoto I, Nakanishi Y, Mori M. Assessment of the albumin-bilirubin grade as a prognostic factor in patients with non-small-cell lung cancer receiving anti-PD-1-based therapy. ESMO Open 2021;7:100348. [PMID: 34942439 DOI: 10.1016/j.esmoop.2021.100348] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
47 Serna-Higuita LM, Amaral T, Forschner A, Leiter U, Flatz L, Seeber O, Thomas I, Garbe C, Eigentler TK, Martus P. Association between Immune-Related Adverse Events and Survival in 319 Stage IV Melanoma Patients Treated with PD-1-Based Immunotherapy: An Approach Based on Clinical Chemistry. Cancers (Basel) 2021;13:6141. [PMID: 34885249 DOI: 10.3390/cancers13236141] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
48 Yamamoto T, Ito T, Hase T, Ishigami M, Mizuno K, Yamamoto K, Imai N, Ishizu Y, Honda T, Shibata H, Hatta T, Yogo N, Yasuda S, Toyoda H, Abe T, Kawashima H, Hashimoto N, Fujishiro M. Immune-related Liver Injury is a Poor Prognostic Factor in Patients with Nonsmall Cell Lung Cancer Treated with Immune Checkpoint Inhibitors. Cancer Invest 2021;:1-10. [PMID: 34658277 DOI: 10.1080/07357907.2021.1994586] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
49 Zou XL, Chen WY, Zhang GY, Ke H, Yang QH, Li XB. Risk Factors, Incidence, and Prognosis of Thromboembolism in Cancer Patients Treated With Immune Checkpoint Inhibitors. Front Pharmacol 2021;12:747075. [PMID: 34819857 DOI: 10.3389/fphar.2021.747075] [Reference Citation Analysis]
50 Wang W, Gu X, Wang L, Pu X, Feng H, Xu C, Lou G, Shao L, Xu Y, Wang Q, Wang S, Gao W, Zhang Y, Song Z. The prognostic impact of mild and severe immune-related adverse events in non-small cell lung cancer treated with immune checkpoint inhibitors: a multicenter retrospective study. Cancer Immunol Immunother 2021. [PMID: 34817639 DOI: 10.1007/s00262-021-03115-y] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
51 Gobbi MF, Eduardo FP, Bezinelli LM, de Carvalho DLC, Monção do Vale SK, Corrêa L. Severe oral ulcerative and lichenoid lesions associated with adrenal insufficiency in a patient treated with nivolumab: Report of a case and review of literature. Spec Care Dentist 2021. [PMID: 34717001 DOI: 10.1111/scd.12660] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
52 Fujisaki T, Watanabe S, Ota T, Kushiro K, Sato Y, Takahashi M, Ohtsubo A, Shoji S, Nozaki K, Ichikawa K, Hokari S, Kondo R, Miyabayashi T, Abe T, Miura S, Tanaka H, Okajima M, Terada M, Matsumoto N, Ishida T, Iwashima A, Sato K, Yoshizawa H, Aoki N, Hayashi M, Ohshima Y, Koya T, Kikuchi T. The Prognostic Significance of the Continuous Administration of Anti-PD-1 Antibody via Continuation or Rechallenge After the Occurrence of Immune-Related Adverse Events. Front Oncol 2021;11:704475. [PMID: 34631533 DOI: 10.3389/fonc.2021.704475] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
53 Kato M, Mori M, Miura K, Asao T, Motomura H, Nishino K, Ko R, Koyama R, Hayashi T, Takahashi K. Dramatic, significant metabolic response to a one-time pembrolizumab treatment following a relapse of pre-existing organizing pneumonia in a patient with advanced non-small cell lung cancer: A case report. Thorac Cancer 2021;12:3076-9. [PMID: 34617405 DOI: 10.1111/1759-7714.14185] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
54 Zhao Z, Wang X, Qu J, Zuo W, Tang Y, Zhu H, Chen X. Immune-Related Adverse Events Associated With Outcomes in Patients With NSCLC Treated With Anti-PD-1 Inhibitors: A Systematic Review and Meta-Analysis. Front Oncol 2021;11:708195. [PMID: 34604047 DOI: 10.3389/fonc.2021.708195] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
55 Chmielewska I, Dudzińska M, Szczyrek M, Świrska J, Wojas-Krawczyk K, Zwolak A. Do endocrine adverse events predict longer progression-free survival among patients with non-small-cell lung cancer receiving nivolumab? PLoS One 2021;16:e0257484. [PMID: 34587185 DOI: 10.1371/journal.pone.0257484] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
56 Huang Y, Soon YY, Aminkeng F, Tay SH, Ang Y, Kee ACL, Goh BC, Wong ASC, Soo RA. Risk factors for immune-related adverse events from anti-PD-1 or anti-PD-L1 treatment in an Asian cohort of nonsmall cell lung cancer patients. Int J Cancer 2021. [PMID: 34562273 DOI: 10.1002/ijc.33822] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
57 He Y, Lu M, Che J, Chu Q, Zhang P, Chen Y. Biomarkers and Future Perspectives for Hepatocellular Carcinoma Immunotherapy. Front Oncol 2021;11:716844. [PMID: 34552872 DOI: 10.3389/fonc.2021.716844] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
58 Foster CC, Couey MA, Kochanny SE, Khattri A, Acharya RK, Tan YC, Brisson RJ, Leidner RS, Seiwert TY. Immune-related adverse events are associated with improved response, progression-free survival, and overall survival for patients with head and neck cancer receiving immune checkpoint inhibitors. Cancer 2021. [PMID: 34547103 DOI: 10.1002/cncr.33780] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
59 Kubo T, Hirohashi Y, Tsukahara T, Kanaseki T, Murata K, Morita R, Torigoe T. Immunopathological basis of immune-related adverse events induced by immune checkpoint blockade therapy. Immunol Med 2021;:1-11. [PMID: 34542015 DOI: 10.1080/25785826.2021.1976942] [Reference Citation Analysis]
60 Kelly K, Manitz J, Patel MR, D'Angelo SP, Apolo AB, Rajan A, Kasturi V, Speit I, Bajars M, Warth J, Gulley JL. Efficacy and immune-related adverse event associations in avelumab-treated patients. J Immunother Cancer 2020;8:e001427. [PMID: 33219092 DOI: 10.1136/jitc-2020-001427] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
61 Sibille A, Henket M, Corhay JL, Alfieri R, Louis R, Duysinx B. White Blood Cells in Patients Treated with Programmed Cell Death-1 Inhibitors for Non-small Cell Lung Cancer. Lung 2021;199:549-57. [PMID: 34518898 DOI: 10.1007/s00408-021-00474-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
62 Russano M, Cortellini A, Giusti R, Russo A, Zoratto F, Rastelli F, Gelibter A, Chiari R, Nigro O, De Tursi M, Bracarda S, Gori S, Grossi F, Bersanelli M, Calvetti L, Di Noia V, Scartozzi M, Di Maio M, Bossi P, Falcone A, Citarella F, Pantano F, Ficorella C, Filetti M, Adamo V, Veltri E, Pergolesi F, Occhipinti MA, Nicolardi L, Tuzi A, Di Marino P, Macrini S, Inno A, Ghidini M, Buti S, Aprile G, Lai E, Audisio M, Intagliata S, Marconcini R, Brocco D, Porzio G, Piras M, Rijavec E, Simionato F, Natoli C, Tiseo M, Vincenzi B, Tonini G, Santini D. Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation. Cancer Immunol Immunother 2021. [PMID: 34462870 DOI: 10.1007/s00262-021-03045-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
63 Stellato M, Procopio G, De Giorgi U, Maruzzo M, Bimbatti D, Mennitto A, Sbrana A, Roviello G, Casadei C, Sepe P, Pignata S, Santini D. Clinical outcome of renal cancer patients who early interrupted immunotherapy due to serious immune-related adverse events. Meet-Uro 13 trial on behalf of the MeetUro investigators. J Transl Med 2021;19:328. [PMID: 34344414 DOI: 10.1186/s12967-021-03008-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
64 Wang M, Zhai X, Li J, Guan J, Xu S, Li Y, Zhu H. The Role of Cytokines in Predicting the Response and Adverse Events Related to Immune Checkpoint Inhibitors. Front Immunol 2021;12:670391. [PMID: 34367136 DOI: 10.3389/fimmu.2021.670391] [Cited by in Crossref: 5] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
65 Toi Y, Kobayashi T, Harada T, Nakagawa T, Mori Y, Kuda T, Sugawara S. Prospective Multicenter Study of Chemotherapy-Induced Clostridium (Clostridioides) difficile Infection in Patients With Lung Cancer: North Japan Lung Cancer Study Group Trial 1204. Front Oncol 2021;11:685320. [PMID: 34336670 DOI: 10.3389/fonc.2021.685320] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
66 Nakashima K, Demura Y, Akai M, Ishizuka T. Long-Term Survival With Pembrolizumab Re-administration After Pseudo-Progression With Immune-Related Interstitial Lung Disease in a Patient With Non-small Cell Lung Cancer. Cureus 2021;13:e16177. [PMID: 34367784 DOI: 10.7759/cureus.16177] [Reference Citation Analysis]
67 Desharnais L, Walsh LA, Quail DF. Exploiting the obesity-associated immune microenvironment for cancer therapeutics. Pharmacol Ther 2021;:107923. [PMID: 34171329 DOI: 10.1016/j.pharmthera.2021.107923] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
68 Wang J, Li Q, Lv H, Nie C, Chen B, Xu W, Yang T, Zhang Y, Tu S, Chen X. A PD-1 Inhibitor Induces Complete Response of Advanced Bladder Urothelial Carcinoma: A Case Report. Front Oncol 2021;11:671416. [PMID: 34221988 DOI: 10.3389/fonc.2021.671416] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
69 Kobayashi K, Iikura Y, Hiraide M, Yokokawa T, Aoyama T, Shikibu S, Hashimoto K, Suzuki K, Sato H, Sugiyama E, Tajima M, Hama T. Association Between Immune-related Adverse Events and Clinical Outcome Following Nivolumab Treatment in Patients With Metastatic Renal Cell Carcinoma. In Vivo 2020;34:2647-52. [DOI: 10.21873/invivo.12083] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
70 Ono K, Ono H, Toi Y, Sugisaka J, Aso M, Saito R, Kawana S, Aiba T, Odaka T, Matsuda S, Saito S, Narumi A, Ogasawara T, Shimizu H, Domeki Y, Terayama K, Kawashima Y, Nakamura A, Yamanda S, Kimura Y, Honda Y, Sugawara S. Association of immune-related pneumonitis with clinical benefit of anti-programmed cell death-1 monotherapy in advanced non-small cell lung cancer. Cancer Med 2021;10:4796-804. [PMID: 34121358 DOI: 10.1002/cam4.4045] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
71 Liu Q, Fang Z, Liu M, Xu R, Yi F, Wei Y, Zeng L, Zhang W. The benefits and risks of CTLA4 inhibitor plus PD1/PDL1 inhibitor in stage IIIB/IV non-small cell lung cancer: A systematic analysis and meta-analysis based on randomized controlled trials. J Clin Pharm Ther 2021. [PMID: 34101874 DOI: 10.1111/jcpt.13465] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
72 Aredo JV, Mambetsariev I, Hellyer JA, Amini A, Neal JW, Padda SK, Mccoach CE, Riess JW, Cabebe EC, Naidoo J, Abuali T, Salgia R, Loo BW, Diehn M, Han SS, Wakelee HA. Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy. Journal of Thoracic Oncology 2021;16:1030-41. [DOI: 10.1016/j.jtho.2021.01.1628] [Cited by in Crossref: 39] [Cited by in F6Publishing: 45] [Article Influence: 19.5] [Reference Citation Analysis]
73 Holstead RG, Kartolo BA, Hopman WM, Baetz TD. Impact of the development of immune related adverse events in metastatic melanoma treated with PD -1 inhibitors. Melanoma Res 2021;31:258-63. [PMID: 33904518 DOI: 10.1097/CMR.0000000000000736] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
74 Huang A, Xu Y, Zang X, Wu C, Gao J, Sun X, Xie M, Ma X, Deng H, Song J, Ren F, Pang L, Qian J, Yu Z, Wan S, Chen Y, Pan L, Zhuang G, Liu S, Xue X. Radiographic features and prognosis of early- and late-onset non-small cell lung cancer immune checkpoint inhibitor-related pneumonitis. BMC Cancer 2021;21:634. [PMID: 34051746 DOI: 10.1186/s12885-021-08353-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
75 Li Y, Zhang Y, Jia X, Jiang P, Mao Z, Liang T, Du Y, Zhang J, Zhang G, Niu G, Guo H. Effect of Immune-Related Adverse Events and Pneumonitis on Prognosis in Advanced Non-Small Cell Lung Cancer: A Comprehensive Systematic Review and Meta-analysis. Clin Lung Cancer 2021:S1525-7304(21)00098-X. [PMID: 34183265 DOI: 10.1016/j.cllc.2021.05.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
76 To KKW, Fong W, Cho WCS. Immunotherapy in Treating EGFR-Mutant Lung Cancer: Current Challenges and New Strategies. Front Oncol 2021;11:635007. [PMID: 34113560 DOI: 10.3389/fonc.2021.635007] [Cited by in Crossref: 29] [Cited by in F6Publishing: 34] [Article Influence: 14.5] [Reference Citation Analysis]
77 Narita T, Hatakeyama S, Numakura K, Kobayashi M, Muto Y, Saito M, Narita S, Tanaka T, Noro D, Tokui N, Yoneyama T, Hashimoto Y, Habuchi T, Ohyama C. Comparison of pembrolizumab with conventional chemotherapy after first-line platinum-based chemotherapy for advanced urothelial carcinoma in real-world practice: A multicenter retrospective study. Int J Urol 2021;28:899-905. [PMID: 34028105 DOI: 10.1111/iju.14601] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
78 Berti A, Bortolotti R, Dipasquale M, Kinspergher S, Prokop L, Grandi G, Inchiostro S, Paolazzi G, Caffo O, Veccia A. Meta-analysis of immune-related adverse events in phase 3 clinical trials assessing immune checkpoint inhibitors for lung cancer. Crit Rev Oncol Hematol 2021;162:103351. [PMID: 33989769 DOI: 10.1016/j.critrevonc.2021.103351] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
79 Oyanagi J, Koh Y, Sato K, Teraoka S, Tokudome N, Hayata A, Akamatsu H, Ozawa Y, Nakanishi M, Ueda H, Yamamoto N. Bloodborne Cytokines for Predicting Clinical Benefits and Immune-Related Adverse Events in Advanced Non-Small Cell Lung Cancer Treated With Anti-Programmed Cell Death 1 Inhibitors. Clin Lung Cancer 2021:S1525-7304(21)00091-7. [PMID: 34049821 DOI: 10.1016/j.cllc.2021.04.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
80 Hata H, Mio T, Yamashita D, Matsumura C, Chisaki Y, Motohashi H, Yano Y. Factors Associated With Efficacy and Nivolumab-Related Interstitial Pneumonia in Non-Small Cell Lung Cancer: A Retrospective Survey. Cancer Control 2020;27:1073274820977200. [PMID: 33297768 DOI: 10.1177/1073274820977200] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
81 Ito S, Asahina H, Honjo O, Tanaka H, Honda R, Oizumi S, Nakamura K, Takamura K, Hommura F, Kawai Y, Ito K, Sukoh N, Yokoo K, Morita R, Harada T, Takashina T, Goda T, Dosaka-Akita H, Isobe H; Hokkaido Lung Cancer Clinical Study Group Trial. Prognostic factors in patients with advanced non-small cell lung cancer after long-term Anti-PD-1 therapy (HOT1902). Lung Cancer 2021;156:12-9. [PMID: 33872943 DOI: 10.1016/j.lungcan.2021.04.011] [Reference Citation Analysis]
82 Fan Y, Xie W, Huang H, Wang Y, Li G, Geng Y, Hao Y, Zhang Z. Association of Immune Related Adverse Events With Efficacy of Immune Checkpoint Inhibitors and Overall Survival in Cancers: A Systemic Review and Meta-analysis. Front Oncol 2021;11:633032. [PMID: 33912454 DOI: 10.3389/fonc.2021.633032] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 9.5] [Reference Citation Analysis]
83 Hirata A, Saraya T, Kobayashi F, Noda A, Aso K, Sakuma S, Kurokawa N, Inoue M, Mikura S, Oda M, Ishida M, Honda K, Nakamoto K, Tamura M, Takata S, Ishii H, Takizawa H. Immune-related adverse events with immune checkpoint inhibitors: Special reference to the effects on the lungs. Medicine (Baltimore) 2021;100:e25275. [PMID: 33832093 DOI: 10.1097/MD.0000000000025275] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
84 Taira K, Kimura A, Nakata A, Nadatani Y, Fukunaga S, Otani K, Hosomi S, Tanaka F, Kamata N, Nagami Y, Watanabe T, Fujiwara Y. A case of nivolumab-induced cervical lymphadenopathy in a patient with gastric cancer. J Gastrointest Oncol 2021;12:880-4. [PMID: 34012675 DOI: 10.21037/jgo-20-315] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
85 Hosoya K, Fujimoto D, Morimoto T, Kumagai T, Tamiya A, Taniguchi Y, Yokoyama T, Ishida T, Matsumoto H, Hirano K, Kominami R, Tomii K, Suzuki H, Hirashima T, Tanaka S, Uchida J, Morita M, Kanazu M, Mori M, Nagata K, Fukuda I, Tamiya M. Clinical factors associated with shorter durable response, and patterns of acquired resistance to first-line pembrolizumab monotherapy in PD-L1-positive non-small-cell lung cancer patients: a retrospective multicenter study. BMC Cancer 2021;21:346. [PMID: 33794809 DOI: 10.1186/s12885-021-08048-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
86 Takada K, Shimokawa M, Takamori S, Shimamatsu S, Hirai F, Tagawa T, Okamoto T, Hamatake M, Tsuchiya-Kawano Y, Otsubo K, Inoue K, Yoneshima Y, Tanaka K, Okamoto I, Nakanishi Y, Mori M. Clinical impact of probiotics on the efficacy of anti-PD-1 monotherapy in patients with nonsmall cell lung cancer: A multicenter retrospective survival analysis study with inverse probability of treatment weighting. Int J Cancer 2021;149:473-82. [PMID: 33720422 DOI: 10.1002/ijc.33557] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 8.5] [Reference Citation Analysis]
87 Liu C, Piao J, Shang Z. Hyperprogressive disease after radiotherapy combined with anti-PD-1 therapy in renal cell carcinoma: a case report and review of the literature. BMC Urol 2021;21:42. [PMID: 33743675 DOI: 10.1186/s12894-021-00813-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
88 Wang X, Niu X, An N, Sun Y, Chen Z. Comparative Efficacy and Safety of Immunotherapy Alone and in Combination With Chemotherapy for Advanced Non-small Cell Lung Cancer. Front Oncol 2021;11:611012. [PMID: 33816241 DOI: 10.3389/fonc.2021.611012] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
89 Umehara K, Yama K, Goto K, Wakamoto A, Hatsuyama T, Honjo O, Saikai T, Fujita A, Sato H. Effect of Systemic Corticosteroid Therapy on the Efficacy and Safety of Nivolumab in the Treatment of Non-Small-Cell Lung Cancer. Cancer Control 2021;28:1073274820985790. [PMID: 33733906 DOI: 10.1177/1073274820985790] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
90 Jing Y, Zhang Y, Wang J, Li K, Chen X, Heng J, Gao Q, Ye Y, Zhang Z, Liu Y, Lou Y, Lin SH, Diao L, Liu H, Chen X, Mills GB, Han L. Association Between Sex and Immune-Related Adverse Events During Immune Checkpoint Inhibitor Therapy. J Natl Cancer Inst 2021:djab035. [PMID: 33705549 DOI: 10.1093/jnci/djab035] [Cited by in Crossref: 17] [Cited by in F6Publishing: 21] [Article Influence: 8.5] [Reference Citation Analysis]
91 Chen X, Nie J, Dai L, Hu W, Zhang J, Han J, Ma X, Tian G, Han S, Wu D, Wang Y, Long J, Zhang Z, Fang J. Immune-Related Adverse Events and Their Association With the Effectiveness of PD-1/PD-L1 Inhibitors in Non-Small Cell Lung Cancer: A Real-World Study From China. Front Oncol 2021;11:607531. [PMID: 33747922 DOI: 10.3389/fonc.2021.607531] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
92 Wang D, Chen C, Gu Y, Lu W, Zhan P, Liu H, Lv T, Song Y, Zhang F. Immune-Related Adverse Events Predict the Efficacy of Immune Checkpoint Inhibitors in Lung Cancer Patients: A Meta-Analysis. Front Oncol 2021;11:631949. [PMID: 33732650 DOI: 10.3389/fonc.2021.631949] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 4.5] [Reference Citation Analysis]
93 Freitas C, Jacob M, Tavares N, Cruz-Martins N, Souto-Moura C, Araújo D, Novais-Bastos H, Santos V, Fernandes G, Magalhães A, Hespanhol V, Queiroga H. Modified Glasgow Prognostic Score predicts survival among advanced non-small cell lung carcinoma patients treated with anti-PD1 agents. Anticancer Drugs 2021;32:567-74. [PMID: 33661189 DOI: 10.1097/CAD.0000000000001060] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
94 Zhong L, Wu Q, Chen F, Liu J, Xie X. Immune-related adverse events: promising predictors for efficacy of immune checkpoint inhibitors. Cancer Immunol Immunother 2021;70:2559-76. [PMID: 33576872 DOI: 10.1007/s00262-020-02803-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
95 Gault A, Anderson A, Plummer R, Stewart C, Pratt A, Rajan N. Cutaneous immune‐related adverse events in patients with melanoma treated with checkpoint inhibitors. Br J Dermatol 2021;185:263-71. [DOI: 10.1111/bjd.19750] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
96 Jeurling S, Cappelli LC. Treatment of immune checkpoint inhibitor-induced inflammatory arthritis. Curr Opin Rheumatol 2020;32:315-20. [PMID: 32168068 DOI: 10.1097/BOR.0000000000000701] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
97 Rose LM, DeBerg HA, Vishnu P, Frankel JK, Manjunath AB, Flores JPE, Aboulafia DM. Incidence of Skin and Respiratory Immune-Related Adverse Events Correlates With Specific Tumor Types in Patients Treated With Checkpoint Inhibitors. Front Oncol 2020;10:570752. [PMID: 33520695 DOI: 10.3389/fonc.2020.570752] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
98 Xu H, Xu X, Ge W, Lei J, Cao D. The association between immune-related adverse events and the prognosis of solid cancer patients treated with immunotherapy: a systematic review and meta-analysis. Ther Adv Med Oncol 2020;12:1758835920980546. [PMID: 33425028 DOI: 10.1177/1758835920980546] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
99 Thuillier P, Joly C, Alavi Z, Crouzeix G, Descourt R, Quere G, Kerlan V, Roudaut N. Thyroid dysfunction induced by immune checkpoint inhibitors is associated with a better progression-free survival and overall survival in non-small cell lung cancer: an original cohort study. Cancer Immunol Immunother 2021;70:2023-33. [PMID: 33423089 DOI: 10.1007/s00262-020-02802-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
100 Takamori S, Takada K, Shimokawa M, Jinnnouchi M, Matsubara T, Haratake N, Miura N, Toyozawa R, Yamaguchi M, Takenoyama M, Yoneshima Y, Tanaka K, Okamoto I, Tagawa T, Mori M. Prognostic impact of primary cancer adjoining emphysematous bullae in non-small cell lung cancer patients treated with immune checkpoint inhibitors. Cancer Immunol Immunother 2021;70:1745-53. [PMID: 33389013 DOI: 10.1007/s00262-020-02783-6] [Reference Citation Analysis]
101 Matsubara T, Yamaguchi M, Jinnouchi M, Takamori S, Fujishita T, Toyozawa R, Ito K, Shimokawa M, Seto T, Okamoto T. Clinical course and prognosis of patients with lung cancer who develop anticancer therapy-related pneumonitis. J Cancer Res Clin Oncol 2021;147:1857-64. [PMID: 33387034 DOI: 10.1007/s00432-020-03478-2] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
102 Hussaini S, Chehade R, Boldt RG, Raphael J, Blanchette P, Maleki Vareki S, Fernandes R. Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors – A systematic review and meta-analysis. Cancer Treatment Reviews 2021;92:102134. [DOI: 10.1016/j.ctrv.2020.102134] [Cited by in Crossref: 76] [Cited by in F6Publishing: 62] [Article Influence: 38.0] [Reference Citation Analysis]
103 Rengarajan M, Gainor JF. Endocrine immune-related adverse events: a double-edged sword? Transl Lung Cancer Res 2021;10:13-7. [PMID: 33569289 DOI: 10.21037/tlcr-2020-16] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
104 Itonaga T, Saito K, Ikeda N, Mikami R. Morphological changes of the thyroid gland as a new radiographic marker for lung cancer treatment efficacy of immune checkpoint inhibitors. Acta Radiol 2021;62:42-50. [PMID: 32268773 DOI: 10.1177/0284185120916197] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
105 Allegra A, Di Salvo E, Casciaro M, Musolino C, Pioggia G, Gangemi S. The Impact of Immunological Checkpoint Inhibitors and Targeted Therapy on Chronic Pruritus in Cancer Patients. Biomedicines 2020;9:2. [PMID: 33375183 DOI: 10.3390/biomedicines9010002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
106 Takamori S, Takada K, Shimokawa M, Matsubara T, Fujishita T, Ito K, Toyozawa R, Yamaguchi M, Okamoto T, Yoneshima Y, Tanaka K, Okamoto I, Tagawa T, Mori M. Clinical utility of pretreatment Glasgow prognostic score in non-small-cell lung cancer patients treated with immune checkpoint inhibitors. Lung Cancer 2021;152:27-33. [PMID: 33341085 DOI: 10.1016/j.lungcan.2020.11.026] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
107 Conde-estévez D, Monge-escartín I, Ríos-hoyo A, Monzonis X, Echeverría-esnal D, Moliner L, Duran-jordà X, Taus Á, Arriola E. Prognostic factors and effect on survival of immune-related adverse events in patients with non-small-cell lung cancer treated with immune checkpoint blockage. Journal of Chemotherapy 2021;33:32-9. [DOI: 10.1080/1120009x.2020.1849488] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
108 Vitale MG, Pipitone S, Venturelli M, Baldessari C, Porta C, Iannuzzi F, Basso U, Scagliarini S, Zucali PA, Galli L, Rossetti S, Caserta C, Bracarda S, Iacovelli R, Masini C, Cortellini A, Di Girolamo S, Buti S, Fornarini G, Carrozza F, Santoni M, Caputo F, Giaquinta S, Balduzzi S, D’amico R, Vitale G, Mighali P, Sabbatini R. Correlation Between Immune-related Adverse Event (IRAE) Occurrence and Clinical Outcome in Patients With Metastatic Renal Cell Carcinoma (mRCC) Treated With Nivolumab: IRAENE Trial, an Italian Multi-institutional Retrospective Study. Clinical Genitourinary Cancer 2020;18:477-88. [DOI: 10.1016/j.clgc.2020.05.010] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
109 Matsuki T, Okamoto I, Fushimi C, Takahashi H, Okada T, Kondo T, Sato H, Ito T, Tokashiki K, Tsukahara K, Hanyu K, Masubuchi T, Tada Y, Miura K, Omura G, Sawabe M, Kawakita D, Yamashita T. Real-World, Long-Term Outcomes of Nivolumab Therapy for Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck and Impact of the Magnitude of Best Overall Response: A Retrospective Multicenter Study of 88 Patients. Cancers (Basel) 2020;12:E3427. [PMID: 33218183 DOI: 10.3390/cancers12113427] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
110 Yatsuda Y, Hirose S, Ito Y, Onoda T, Sugiyama Y, Nagafuchi M, Suzuki H, Niisato Y, Tange Y, Ikeda T, Yamada T, Yamamoto Y, Ohyama Osawa M, Sakamoto N, Moriwaki T, Mizokami Y. A Durable Response after the Discontinuation of Nivolumab in an Advanced Gastric Cancer Patient. Intern Med 2021;60:1011-7. [PMID: 33162479 DOI: 10.2169/internalmedicine.5893-20] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
111 Riudavets M, Caramella C, Pradere P, Naltet C, Le Pechoux C, Adam J, Mabille L, Rouleau E, Besse B, Planchard D. Complete, Unpredictable, Multi-site Response Including Brain and Liver Metastases in a Patient With RET-rearranged Non-small-cell Lung Cancer Treated With Single-agent Immunotherapy: A Case Report. Clin Lung Cancer 2021;22:e215-9. [PMID: 33187915 DOI: 10.1016/j.cllc.2020.10.011] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
112 Huang L, Li L, Zhou Y, Yang Z, Wang M, Gao Y, Yang Y, Yang F, Liu B, Hong X, Chen G. Clinical Characteristics Correlate With Outcomes of Immunotherapy in Advanced Non-Small Cell Lung Cancer. J Cancer 2020;11:7137-45. [PMID: 33193876 DOI: 10.7150/jca.49213] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
113 Sesma A, Pardo J, Cruellas M, Gálvez EM, Gascón M, Isla D, Martínez-Lostao L, Ocáriz M, Paño JR, Quílez E, Ramírez A, Torres-Ramón I, Yubero A, Zapata M, Lastra R. From Tumor Mutational Burden to Blood T Cell Receptor: Looking for the Best Predictive Biomarker in Lung Cancer Treated with Immunotherapy. Cancers (Basel) 2020;12:E2974. [PMID: 33066479 DOI: 10.3390/cancers12102974] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
114 Schweizer C, Schubert P, Rutzner S, Eckstein M, Haderlein M, Lettmaier S, Semrau S, Gostian AO, Frey B, Gaipl US, Zhou JG, Fietkau R, Hecht M. Prospective evaluation of the prognostic value of immune-related adverse events in patients with non-melanoma solid tumour treated with PD-1/PD-L1 inhibitors alone and in combination with radiotherapy. Eur J Cancer 2020;140:55-62. [PMID: 33045663 DOI: 10.1016/j.ejca.2020.09.001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
115 Silvestris N, Argentiero A, Beretta GD, Di Bartolo P, Montagnani M, Danesi R, Ferrari P, D'Oronzo S, Gori S, Russo A, Acquati S, Gallo M. Management of metabolic adverse events of targeted therapies and immune checkpoint inhibitors in cancer patients: an Associazione Italiana Oncologia Medica (AIOM)/Associazione Medici Diabetologi (AMD)/Società Italiana Farmacologia (SIF) multidisciplinary consensus position paper. Crit Rev Oncol Hematol 2020;154:103066. [PMID: 32853883 DOI: 10.1016/j.critrevonc.2020.103066] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
116 Shen Y, Chen Y, Wang D, Zhu Z. Treatment-related adverse events as surrogate to response rate to immune checkpoint blockade. Medicine (Baltimore) 2020;99:e22153. [PMID: 32925773 DOI: 10.1097/MD.0000000000022153] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
117 Ocáriz-Díez M, Cruellas M, Gascón M, Lastra R, Martínez-Lostao L, Ramírez-Labrada A, Paño JR, Sesma A, Torres I, Yubero A, Pardo J, Isla D, Gálvez EM. Microbiota and Lung Cancer. Opportunities and Challenges for Improving Immunotherapy Efficacy. Front Oncol 2020;10:568939. [PMID: 33117698 DOI: 10.3389/fonc.2020.568939] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
118 Economopoulou P, Kotsantis I, Papaxoinis G, Gavrielatou N, Anastasiou M, Pantazopoulos A, Kavourakis G, Gkolfinopoulos S, Panayiotides I, Delides A, Psyrri A. Association of autoimmunity with survival in patients with recurrent/metastatic head and neck squamous cell carcinoma treated with nivolumab. Oral Oncol 2020;111:105013. [PMID: 32977184 DOI: 10.1016/j.oraloncology.2020.105013] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
119 Yamamoto Y, Yatsuda J, Shimokawa M, Fuji N, Aoki A, Sakano S, Yamamoto M, Suga A, Tei Y, Yoshihiro S, Kitahara S, Nagao K, Takai K, Kamiryo Y, Akao J, Yamaguchi S, Oba K, Shimabukuro T, Matsumoto H, Kamba T, Matsuyama H. Prognostic value of pre-treatment risk stratification and post-treatment neutrophil/lymphocyte ratio change for pembrolizumab in patients with advanced urothelial carcinoma. Int J Clin Oncol 2021;26:169-77. [PMID: 32948925 DOI: 10.1007/s10147-020-01784-w] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
120 Sumi T, Uehara H, Masaoka T, Tada M, Keira Y, Kamada K, Shijubou N, Yamada Y, Nakata H, Mori Y, Chiba H. Lung adenocarcinoma with tumor resolution and dystrophic calcification after salvage surgery following immune checkpoint inhibitor therapy: A case report. Thorac Cancer 2020;11:3396-400. [PMID: 32930490 DOI: 10.1111/1759-7714.13663] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
121 Riudavets M, Mosquera J, Garcia-Campelo R, Serra J, Anguera G, Gallardo P, Sullivan I, Barba A, Del Carpio L, Barnadas A, Gich I, Majem M. Immune-Related Adverse Events and Corticosteroid Use for Cancer-Related Symptoms Are Associated With Efficacy in Patients With Non-small Cell Lung Cancer Receiving Anti-PD-(L)1 Blockade Agents. Front Oncol 2020;10:1677. [PMID: 33014837 DOI: 10.3389/fonc.2020.01677] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
122 Yokohama K, Asai A, Matsui M, Okamoto N, Yasuoka H, Nishikawa T, Ohama H, Tsuchimoto Y, Inoue Y, Fukunishi S, Uchiyama K, Higuchi K. Liver dysfunction is associated with poor prognosis in patients after immune checkpoint inhibitor therapy. Sci Rep 2020;10:14470. [PMID: 32879383 DOI: 10.1038/s41598-020-71561-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
123 Martin C, Lupinacci L, Perazzo F, Bas C, Carranza O, Puparelli C, Kowalyszyn R, Magri I, Varela M, Richardet E, Vera K, Foglia S, Jerez I, Aman E, Martinengo G, Batagelj E, Dri A, Pilnik N, Roa GM, Mando P, Tsou F, Recondo G, Cayol F, Flores M, Sena S, Bagnes C, Waisberg FD, Minatta JN, Rizzo M. Efficacy and Safety of Nivolumab in Previously Treated Patients With Non–Small-cell Lung Cancer: Real World Experience in Argentina. Clinical Lung Cancer 2020;21:e380-7. [DOI: 10.1016/j.cllc.2020.02.014] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
124 Sakamoto K, Fukihara J, Morise M, Hashimoto N. Clinical burden of immune checkpoint inhibitor-induced pneumonitis. Respiratory Investigation 2020;58:305-19. [DOI: 10.1016/j.resinv.2020.05.008] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
125 Tambo Y, Sone T, Shibata K, Nishi K, Shirasaki H, Yoneda T, Araya T, Kase K, Nishikawa S, Kimura H, Kasahara K. Real-World Efficacy of First-Line Pembrolizumab in Patients With Advanced or Recurrent Non–Small-Cell Lung Cancer and High PD-L1 Tumor Expression. Clinical Lung Cancer 2020;21:e366-79. [DOI: 10.1016/j.cllc.2020.02.017] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 6.3] [Reference Citation Analysis]
126 Pico de Coaña Y, Wolodarski M, van der Haar Àvila I, Nakajima T, Rentouli S, Lundqvist A, Masucci G, Hansson J, Kiessling R. PD-1 checkpoint blockade in advanced melanoma patients: NK cells, monocytic subsets and host PD-L1 expression as predictive biomarker candidates. Oncoimmunology 2020;9:1786888. [PMID: 32939320 DOI: 10.1080/2162402X.2020.1786888] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 5.7] [Reference Citation Analysis]
127 Bai R, Lv Z, Xu D, Cui J. Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors. Biomark Res 2020;8:34. [PMID: 32864131 DOI: 10.1186/s40364-020-00209-0] [Cited by in Crossref: 123] [Cited by in F6Publishing: 138] [Article Influence: 41.0] [Reference Citation Analysis]
128 Albrethsen M, Creeden J, Morand S, DeBiase J, Berry B, Stanbery L, Edelman G, Nemunaitis J. Relationship of hypothyroidism and immune response to pegylated IL-10/nivolumab. Immunotherapy 2020;12:1041-6. [PMID: 32808556 DOI: 10.2217/imt-2020-0016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
129 Dudzińska M, Szczyrek M, Wojas-Krawczyk K, Świrska J, Chmielewska I, Zwolak A. Endocrine Adverse Events of Nivolumab in Non-Small Cell Lung Cancer Patients-Literature Review. Cancers (Basel) 2020;12:E2314. [PMID: 32824462 DOI: 10.3390/cancers12082314] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
130 Raimondi A, Sepe P, Zattarin E, Mennitto A, Stellato M, Claps M, Guadalupi V, Verzoni E, de Braud F, Procopio G. Predictive Biomarkers of Response to Immunotherapy in Metastatic Renal Cell Cancer. Front Oncol 2020;10:1644. [PMID: 32903369 DOI: 10.3389/fonc.2020.01644] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 7.3] [Reference Citation Analysis]
131 Garrett NFMDS, da Costa ACC, Damiani G, Vasques CI. Patients with lung cancer undergoing immune checkpoint inhibitors: A meta-analysis of dermatological toxicities. Critical Reviews in Oncology/Hematology 2020;152:102983. [DOI: 10.1016/j.critrevonc.2020.102983] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
132 Li H, Zhou X, Zhang D, Wang G, Cheng X, Xu C, Yao B, Pang L, Chen J. Early Onset Immune-Related Adverse Event to Identify Pseudo-Progression in a Patient With Ovarian Cancer Treated With Nivolumab: A Case Report and Review of the Literature. Front Med (Lausanne) 2020;7:366. [PMID: 32850889 DOI: 10.3389/fmed.2020.00366] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
133 Mangan BL, McAlister RK, Balko JM, Johnson DB, Moslehi JJ, Gibson A, Phillips EJ. Evolving insights into the mechanisms of toxicity associated with immune checkpoint inhibitor therapy. Br J Clin Pharmacol 2020;86:1778-89. [PMID: 32543711 DOI: 10.1111/bcp.14433] [Cited by in Crossref: 17] [Cited by in F6Publishing: 21] [Article Influence: 5.7] [Reference Citation Analysis]
134 Zhao B, Zhao H, Zhao J. Efficacy of PD-1/PD-L1 blockade monotherapy in clinical trials. Ther Adv Med Oncol 2020;12:1758835920937612. [PMID: 32728392 DOI: 10.1177/1758835920937612] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 11.0] [Reference Citation Analysis]
135 Kijima T, Fukushima H, Kusuhara S, Tanaka H, Yoshida S, Yokoyama M, Ishioka J, Matsuoka Y, Numao N, Sakai Y, Saito K, Matsubara N, Yuasa T, Masuda H, Yonese J, Kageyama Y, Fujii Y. Association Between the Occurrence and Spectrum of Immune-Related Adverse Events and Efficacy of Pembrolizumab in Asian Patients With Advanced Urothelial Cancer: Multicenter Retrospective Analyses and Systematic Literature Review. Clin Genitourin Cancer 2021;19:208-216.e1. [PMID: 32800718 DOI: 10.1016/j.clgc.2020.07.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
136 Noguchi S, Suminaga K, Kaki T, Kawachi H, Fukao A, Terashita S, Horikawa S, Ikeue T, Sugita T. Correlation of Immune-Related Adverse Events and Effects of Pembrolizumab Monotherapy in Patients with Non-Small Cell Lung Cancer. Lung Cancer (Auckl) 2020;11:53-7. [PMID: 32765147 DOI: 10.2147/LCTT.S254146] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
137 Bouhlel L, Doyen J, Chamorey E, Poudenx M, Ilie M, Gal J, Guigay J, Benzaquen J, Marquette CH, Berthet JP, Mouroux J, Schiappa R, Padovani B, Hofman P, Otto J. Occurrence and number of immune-related adverse events are independently associated with survival in advanced non-small-cell lung cancer treated by nivolumab. Bull Cancer 2020;107:946-58. [PMID: 32646604 DOI: 10.1016/j.bulcan.2020.04.019] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
138 Yen CJ, Kiyota N, Hanai N, Takahashi S, Yokota T, Iwae S, Shimizu Y, Hong RL, Goto M, Kang JH, Li WSK, Ferris RL, Gillison M, Endo T, Jayaprakash V, Tahara M. Two-year follow-up of a randomized phase III clinical trial of nivolumab vs. the investigator's choice of therapy in the Asian population for recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141). Head Neck 2020;42:2852-62. [PMID: 32583557 DOI: 10.1002/hed.26331] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 5.7] [Reference Citation Analysis]
139 Cortellini A, Friedlaender A, Banna GL, Porzio G, Bersanelli M, Cappuzzo F, Aerts JGJV, Giusti R, Bria E, Cortinovis D, Grossi F, Migliorino MR, Galetta D, Passiglia F, Berardi R, Mazzoni F, Di Noia V, Signorelli D, Tuzi A, Gelibter A, Marchetti P, Macerelli M, Rastelli F, Chiari R, Rocco D, Inno A, Di Marino P, Mansueto G, Zoratto F, Santoni M, Tudini M, Ghidini M, Filetti M, Catino A, Pizzutilo P, Sala L, Occhipinti MA, Citarella F, Russano M, Torniai M, Cantini L, Follador A, Sforza V, Nigro O, Ferrara MG, D'Argento E, Leonetti A, Pettoruti L, Antonuzzo L, Scodes S, Landi L, Guaitoli G, Baldessari C, Bertolini F, Della Gravara L, Dal Bello MG, Belderbos RA, De Filippis M, Cecchi C, Ricciardi S, Donisi C, De Toma A, Proto C, Addeo A, Cantale O, Ricciuti B, Genova C, Morabito A, Santini D, Ficorella C, Cannita K. Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes. Clin Lung Cancer 2020;21:498-508.e2. [PMID: 32680806 DOI: 10.1016/j.cllc.2020.06.010] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 11.0] [Reference Citation Analysis]
140 Tatsumi A, Maekawa Y, Komori Y, Yamamoto K, Hamaguchi T, Takahashi K, Kunimasa J. Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio as Predictive Factors for Serious Nivolumab-Induced Immune-Related Adverse Events. Jpn J Pharm Health Care Sci 2020;46:331-339. [DOI: 10.5649/jjphcs.46.331] [Reference Citation Analysis]
141 Zhao JJ, Wen XZ, Ding Y, Li DD, Zhu BY, Li JJ, Weng DS, Zhang X, Zhang XS. Association between immune-related adverse events and efficacy of PD-1 inhibitors in Chinese patients with advanced melanoma. Aging (Albany NY) 2020;12:10663-75. [PMID: 32516130 DOI: 10.18632/aging.103285] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
142 Okamoto I, Sato H, Tsukahara K. DUPLICATE: Overall survival and PD-L1 expression in patients with recurrent or metastatic head and neck cancer treated with nivolumab. Auris Nasus Larynx 2020:S0385-8146(20)30090-0. [PMID: 32507527 DOI: 10.1016/j.anl.2020.02.018] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
143 Park R, Lopes L, Saeed A. Anti-PD-1/L1-associated immune-related adverse events as harbinger of favorable clinical outcome: systematic review and meta-analysis. Clin Transl Oncol 2021;23:100-9. [DOI: 10.1007/s12094-020-02397-5] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
144 Kopecký J, Kubeček O. How to manage side effects of immunotherapy. Onkologie 2020;14:6-12. [DOI: 10.36290/xon.2020.049] [Reference Citation Analysis]
145 Okamoto I, Sato H, Tsukahara K. Overall survival and PD-L1 expression in patients with recurrent or metastatic head and neck cancer treated with nivolumab. Auris Nasus Larynx 2020;47:676-86. [PMID: 32439271 DOI: 10.1016/j.anl.2020.04.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
146 Vitale G, Lamberti G, Comito F, Di Nunno V, Massari F, Morelli MC, Ardizzoni A, Gelsomino F. Anti-programmed cell death-1 and anti-programmed cell death ligand-1 immune-related liver diseases: from clinical pivotal studies to real-life experience. Expert Opin Biol Ther 2020;20:1047-59. [PMID: 32425081 DOI: 10.1080/14712598.2020.1762562] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
147 Takamori S, Takada K, Shimokawa M, Matsubara T, Haratake N, Miura N, Toyozawa R, Yamaguchi M, Takenoyama M, Yoneshima Y, Tanaka K, Okamoto I, Tagawa T, Mori M. Predictive and prognostic impact of primary tumor-bearing lobe in nonsmall cell lung cancer patients treated with anti-PD-1 therapy. Int J Cancer 2020;147:2327-34. [PMID: 32356560 DOI: 10.1002/ijc.33030] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
148 Yamamoto Y, Matsuyama H, Matsumoto H, Sakano S, Fuji N, Oba K, Yamamoto M, Kamiryo Y, Hiragino T, Nagao K, Takai K, Aoki A. Prognostic value of risk stratification using blood parameters for nivolumab in Japanese patients with metastatic renal-cell carcinoma. Jpn J Clin Oncol 2020;50:214-20. [PMID: 31755525 DOI: 10.1093/jjco/hyz168] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
149 Lim SM, Kim SW, Cho BC, Kang JH, Ahn MJ, Kim DW, Kim YC, Lee JS, Lee JS, Lee SY, Park KU, An HJ, Cho EK, Jang TW, Kim BS, Kim JH, Lee SS, Na II, Yoo SS, Lee KH. Real-World Experience of Nivolumab in Non-small Cell Lung Cancer in Korea. Cancer Res Treat 2020;52:1112-9. [PMID: 32599984 DOI: 10.4143/crt.2020.245] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
150 Takada K, Toyokawa G, Kinoshita F, Jogo T, Kohashi K, Wakasu S, Ono Y, Tanaka K, Oba T, Osoegawa A, Tagawa T, Azuma K, Okamoto I, Shimokawa M, Oda Y, Mori M. Expression of PD-L1, PD-L2, and IDO1 on tumor cells and density of CD8-positive tumor-infiltrating lymphocytes in early-stage lung adenocarcinoma according to histological subtype. J Cancer Res Clin Oncol 2020;146:2639-50. [PMID: 32405745 DOI: 10.1007/s00432-020-03250-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
151 Friedlaender A, Kim C, Addeo A. Rethinking the Optimal Duration of Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer Throughout the COVID-19 Pandemic. Front Oncol 2020;10:862. [PMID: 32574277 DOI: 10.3389/fonc.2020.00862] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
152 Cui P, Huang D, Wu Z, Tao H, Zhang S, Ma J, Liu Z, Wang J, Huang Z, Chen S, Zheng X, Hu Y. Association of immune-related pneumonitis with the efficacy of PD-1/PD-L1 inhibitors in non-small cell lung cancer. Ther Adv Med Oncol 2020;12:1758835920922033. [PMID: 32426052 DOI: 10.1177/1758835920922033] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
153 Takada K, Takamori S, Yoneshima Y, Tanaka K, Okamoto I, Shimokawa M, Oba T, Osoegawa A, Tagawa T, Takenoyama M, Oda Y, Nakanishi Y, Mori M. Serum markers associated with treatment response and survival in non-small cell lung cancer patients treated with anti-PD-1 therapy. Lung Cancer 2020;145:18-26. [PMID: 32388276 DOI: 10.1016/j.lungcan.2020.04.034] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 10.0] [Reference Citation Analysis]
154 Wang L, Abbas M, Wang F, Mikrani R, Li X, Fan L, Wang X, Shi M. Real-life experience with nivolumab monotherapy in patients with advanced lung cancer: Efficacy and immune-related adverse events at Jiangsu Cancer Hospital, Nanjing, China. Current Medicine Research and Practice 2020;10:93-9. [DOI: 10.1016/j.cmrp.2020.05.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
155 Collins M, Soularue E, Marthey L, Carbonnel F. Management of Patients With Immune Checkpoint Inhibitor-Induced Enterocolitis: A Systematic Review. Clin Gastroenterol Hepatol 2020;18:1393-1403.e1. [PMID: 32007539 DOI: 10.1016/j.cgh.2020.01.033] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 8.3] [Reference Citation Analysis]
156 Basak EA, van der Meer JWM, Hurkmans DP, Schreurs MWJ, Oomen-de Hoop E, van der Veldt AAM, Bins S, Joosse A, Koolen SLW, Debets R, Peeters RP, Aerts JGJV, Mathijssen RHJ, Medici M. Overt Thyroid Dysfunction and Anti-Thyroid Antibodies Predict Response to Anti-PD-1 Immunotherapy in Cancer Patients. Thyroid 2020;30:966-73. [PMID: 32151195 DOI: 10.1089/thy.2019.0726] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 10.3] [Reference Citation Analysis]
157 Botticelli A, Mezi S, Pomati G, Sciattella P, Cerbelli B, Roberto M, Mammone G, Cirillo A, Cassano A, Di Dio C, Cortellini A, Pizzuti L, Ronzino G, Salati M, Vici P, Polimeni A, Merlano MC, Nuti M, Marchetti P. The Impact of Locoregional Treatment on Response to Nivolumab in Advanced Platinum Refractory Head and Neck Cancer: The Need Trial. Vaccines (Basel) 2020;8:E191. [PMID: 32326034 DOI: 10.3390/vaccines8020191] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
158 Liu Y, Zhang T, Gao Y, Qu Y, Lu B, Zhang H, Wang Q, Li J, Hu F, Li B. [A Single Center Analysis of Advanced Non-small Cell Lung Cancer Patients Treated with Immunotherapy in Real-world Practice]. Zhongguo Fei Ai Za Zhi 2019;22:687-95. [PMID: 31771737 DOI: 10.3779/j.issn.1009-3419.2019.11.02] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
159 Suzuki Y, Karayama M, Uto T, Fujii M, Matsui T, Asada K, Kusagaya H, Kato M, Matsuda H, Matsuura S, Toyoshima M, Mori K, Ito Y, Koyauchi T, Yasui H, Hozumi H, Furuhashi K, Enomoto N, Fujisawa T, Nakamura Y, Inui N, Suda T. Assessment of Immune-Related Interstitial Lung Disease in Patients With NSCLC Treated with Immune Checkpoint Inhibitors: A Multicenter Prospective Study. J Thorac Oncol 2020;15:1317-27. [PMID: 32289515 DOI: 10.1016/j.jtho.2020.04.002] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 6.3] [Reference Citation Analysis]
160 Suzuki K, Yanagihara T, Matsumoto K, Kusaba H, Yamauchi T, Ikematsu Y, Tanaka K, Otsubo K, Inoue H, Yoneshima Y, Iwama E, Arimura-Omori M, Harada E, Hamada N, Okamoto I, Nakanishi Y. Immune-checkpoint profiles for T cells in bronchoalveolar lavage fluid of patients with immune-checkpoint inhibitor-related interstitial lung disease. Int Immunol 2020;32:547-57. [PMID: 32253426 DOI: 10.1093/intimm/dxaa022] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
161 Abu-sbeih H, Tang T, Ali FS, Johnson DH, Qiao W, Diab A, Wang Y. The Impact of Immune Checkpoint Inhibitor-Related Adverse Events and Their Immunosuppressive Treatment on Patients’ Outcomes. Journal of Immunotherapy and Precision Oncology 2018;1:7-18. [DOI: 10.4103/jipo.jipo_12_18] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 8.7] [Reference Citation Analysis]
162 Kacew AJ, Harris EJ, Lorch JH, Schoenfeld JD, Margalit DN, Kass JI, Tishler RB, Haddad RI, Hanna GJ. Chemotherapy after immune checkpoint blockade in patients with recurrent, metastatic squamous cell carcinoma of the head and neck. Oral Oncol 2020;105:104676. [PMID: 32251982 DOI: 10.1016/j.oraloncology.2020.104676] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
163 Ida H, Goto Y, Sato J, Kanda S, Shinno Y, Morita R, Murakami S, Matsumoto Y, Yoshida T, Horinouchi H, Fujiwara Y, Yamamoto N, Fukuda T, Ohashi K, Ohe Y. Clinical characteristics of adrenal insufficiency as an immune-related adverse event in non-small-cell lung cancer. Med Oncol 2020;37:30. [PMID: 32180046 DOI: 10.1007/s12032-020-01357-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
164 Xia L, Liu Y, Wang Y. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions. Oncologist 2019;24:S31-41. [PMID: 30819829 DOI: 10.1634/theoncologist.2019-IO-S1-s05] [Cited by in Crossref: 102] [Cited by in F6Publishing: 133] [Article Influence: 34.0] [Reference Citation Analysis]
165 Sugano T, Seike M, Saito Y, Kashiwada T, Terasaki Y, Takano N, Hisakane K, Takahashi S, Tanaka T, Takeuchi S, Miyanaga A, Minegishi Y, Noro R, Kubota K, Gemma A. Immune checkpoint inhibitor-associated interstitial lung diseases correlate with better prognosis in patients with advanced non-small-cell lung cancer. Thorac Cancer 2020;11:1052-60. [PMID: 32096610 DOI: 10.1111/1759-7714.13364] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 7.3] [Reference Citation Analysis]
166 Chen YM, Chih-Hsin Yang J, Su WC, Chong IW, Hsia TC, Lin MC, Chang GC, Chiu CH, Ho CC, Wu SY, Hung JY, Wang CC, Yang TY, Yu CJ. Nivolumab safety and efficacy in advanced, platinum-resistant, non-small cell lung cancer, radical radiotherapy-ineligible patients: A phase II study in Taiwan. J Formos Med Assoc 2020;119:1817-26. [PMID: 32094063 DOI: 10.1016/j.jfma.2020.01.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
167 Berner F, Bomze D, Diem S, Ali OH, Fässler M, Ring S, Niederer R, Ackermann CJ, Baumgaertner P, Pikor N, Cruz CG, van de Veen W, Akdis M, Nikolaev S, Läubli H, Zippelius A, Hartmann F, Cheng HW, Hönger G, Recher M, Goldman J, Cozzio A, Früh M, Neefjes J, Driessen C, Ludewig B, Hegazy AN, Jochum W, Speiser DE, Flatz L. Association of Checkpoint Inhibitor-Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non-Small Cell Lung Cancer. JAMA Oncol 2019;5:1043-7. [PMID: 31021392 DOI: 10.1001/jamaoncol.2019.0402] [Cited by in Crossref: 164] [Cited by in F6Publishing: 174] [Article Influence: 54.7] [Reference Citation Analysis]
168 Pantano F, Russano M, Berruti A, Mansueto G, Migliorino MR, Adamo V, Aprile G, Gelibter A, Ficorella C, Falcone A, Russo A, Aieta M, Maio M, Martelli O, Barni S, Napolitano A, Roca E, Quadrini S, Iacono D, Russo A, Calvetti L, Occhipinti MA, Cortellini A, Vasile E, Passiglia F, Imperatori M, Calabrò L, Di Giacomo AM, Petrelli F, Pasquini G, Franchina T, Venditti O, Intagliata S, Galvano A, Fioroni I, Vincenzi B, Tonini G, Santini D. Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving Nivolumab. Expert Opin Biol Ther 2020;20:319-26. [PMID: 32011207 DOI: 10.1080/14712598.2020.1724953] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
169 Takada K, Yoneshima Y, Tanaka K, Okamoto I, Shimokawa M, Wakasu S, Takamori S, Toyokawa G, Oba T, Osoegawa A, Tagawa T, Oda Y, Nakanishi Y, Mori M. Clinical impact of skeletal muscle area in patients with non-small cell lung cancer treated with anti-PD-1 inhibitors. J Cancer Res Clin Oncol 2020;146:1217-25. [PMID: 32025867 DOI: 10.1007/s00432-020-03146-5] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 7.3] [Reference Citation Analysis]
170 Hosoya K, Fujimoto D, Morimoto T, Kumagai T, Tamiya A, Taniguchi Y, Yokoyama T, Ishida T, Hirano K, Matsumoto H, Kominami R, Tomii K, Suzuki H, Hirashima T, Uchida J, Morita M, Kanazu M, Sawa N, Makio T, Hara S, Tamiya M. Association Between Early Immune-related Adverse Events and Clinical Outcomes in Patients With Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors. Clin Lung Cancer 2020;21:e315-28. [PMID: 32113737 DOI: 10.1016/j.cllc.2020.01.003] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 7.3] [Reference Citation Analysis]
171 Saleh K, Khalife-Saleh N, Kourie HR. Do immune-related adverse events correlate with response to immune checkpoint inhibitors? Immunotherapy 2019;11:257-9. [PMID: 30678551 DOI: 10.2217/imt-2018-0201] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
172 Kim KH, Hur JY, Cho J, Ku BM, Koh J, Koh JY, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ, Shin EC. Immune-related adverse events are clustered into distinct subtypes by T-cell profiling before and early after anti-PD-1 treatment. Oncoimmunology 2020;9:1722023. [PMID: 32076579 DOI: 10.1080/2162402X.2020.1722023] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 6.3] [Reference Citation Analysis]
173 Lim SM, Hong MH, Kim HR. Immunotherapy for Non-small Cell Lung Cancer: Current Landscape and Future Perspectives. Immune Netw 2020;20:e10. [PMID: 32158598 DOI: 10.4110/in.2020.20.e10] [Cited by in Crossref: 58] [Cited by in F6Publishing: 64] [Article Influence: 19.3] [Reference Citation Analysis]
174 Otsuka M, Sugihara S, Mori S, Hamada K, Sasaki Y, Yoshikawa S, Kiyohara Y. Immune-related adverse events correlate with improved survival in patients with advanced mucosal melanoma treated with nivolumab: A single-center retrospective study in Japan. J Dermatol 2020;47:356-62. [PMID: 31984569 DOI: 10.1111/1346-8138.15246] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
175 Teratake Y, Takashina T, Iijima K, Sakuma T, Yamamoto T, Ishizaka Y. Development of a protein-based system for transient epigenetic repression of immune checkpoint molecule and enhancement of antitumour activity of natural killer cells. Br J Cancer 2020;122:823-34. [PMID: 31959920 DOI: 10.1038/s41416-019-0708-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
176 Sugisaka J, Toi Y, Taguri M, Kawashima Y, Aiba T, Kawana S, Saito R, Aso M, Tsurumi K, Suzuki K, Shimizu H, Ono H, Domeki Y, Terayama K, Nakamura A, Yamanda S, Kimura Y, Honda Y, Sugawara S. Relationship between Programmed Cell Death Protein Ligand 1 Expression and Immune-related Adverse Events in Non-small-cell Lung Cancer Patients Treated with Pembrolizumab. JMA J 2020;3:58-66. [PMID: 33324776 DOI: 10.31662/jmaj.2019-0005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
177 Das S, Ciombor KK, Haraldsdottir S, Pumpalova Y, Sahin IH, Pineda G, Shyr Y, Lin EP, Hsu CY, Chu SK, Goff LW, Cardin DB, Bilen MA, Fisher GA, Wu C, Berlin J. Immune-Related Adverse Events and Immune Checkpoint Inhibitor Efficacy in Patients with Gastrointestinal Cancer with Food and Drug Administration-Approved Indications for Immunotherapy. Oncologist 2020;25:669-79. [PMID: 31943525 DOI: 10.1634/theoncologist.2019-0637] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 5.3] [Reference Citation Analysis]
178 Raschi E, Mazzarella A, Antonazzo IC, Bendinelli N, Forcesi E, Tuccori M, Moretti U, Poluzzi E, De Ponti F. Toxicities with Immune Checkpoint Inhibitors: Emerging Priorities from Disproportionality Analysis of the FDA Adverse Event Reporting System. Target Oncol. 2019;14:205-221. [PMID: 30927173 DOI: 10.1007/s11523-019-00632-w] [Cited by in Crossref: 52] [Cited by in F6Publishing: 47] [Article Influence: 17.3] [Reference Citation Analysis]
179 Cortellini A, Buti S, Bersanelli M, Giusti R, Perrone F, Di Marino P, Tinari N, De Tursi M, Grassadonia A, Cannita K, Tessitore A, Zoratto F, Veltri E, Malorgio F, Russano M, Anesi C, Zeppola T, Filetti M, Marchetti P, Botticelli A, Cappellini GCA, De Galitiis F, Vitale MG, Rastelli F, Pergolesi F, Berardi R, Rinaldi S, Tudini M, Silva RR, Pireddu A, Atzori F, Iacono D, Migliorino MR, Gelibter A, Occhipinti MA, Martella F, Inno A, Gori S, Bracarda S, Zannori C, Mosillo C, Parisi A, Porzio G, Mallardo D, Fargnoli MC, Tiseo M, Santini D, Ascierto PA, Ficorella C. Evaluating the role of FAMIly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study. Oncoimmunology 2020;9:1710389. [PMID: 32002308 DOI: 10.1080/2162402X.2019.1710389] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
180 Ashinuma H, Mizuno S, Yoshida Y, Shingyoji M. A Case of Long-Term Survival after Checkpoint Inhibitor Pneumonitis in a Patient with Squamous Cell Lung Cancer. Case Rep Oncol Med 2019;2019:4836404. [PMID: 31949964 DOI: 10.1155/2019/4836404] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
181 Matsuo M, Yasumatsu R, Masuda M, Toh S, Wakasaki T, Hashimoto K, Taura M, Uchi R, Nakagawa T. Relationship between immune-related adverse events and the long-term outcomes in recurrent/metastatic head and neck squamous cell carcinoma treated with nivolumab. Oral Oncol 2020;101:104525. [PMID: 31863963 DOI: 10.1016/j.oraloncology.2019.104525] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 6.5] [Reference Citation Analysis]
182 Tai D, Choo SP, Chew V. Rationale of Immunotherapy in Hepatocellular Carcinoma and Its Potential Biomarkers. Cancers (Basel) 2019;11:E1926. [PMID: 31816940 DOI: 10.3390/cancers11121926] [Cited by in Crossref: 18] [Cited by in F6Publishing: 22] [Article Influence: 4.5] [Reference Citation Analysis]
183 Akamatsu H, Murakami E, Oyanagi J, Shibaki R, Kaki T, Takase E, Tanaka M, Harutani Y, Yamagata N, Okuda Y, Furuta K, Sugimoto T, Teraoka S, Hayata A, Tokudome N, Ozawa Y, Mori K, Koh Y, Yamamoto N. Immune-Related Adverse Events by Immune Checkpoint Inhibitors Significantly Predict Durable Efficacy Even in Responders with Advanced Non-Small Cell Lung Cancer. Oncologist 2020;25:e679-83. [PMID: 32297443 DOI: 10.1634/theoncologist.2019-0299] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 7.0] [Reference Citation Analysis]
184 Das S, Johnson DB. Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors. J Immunother Cancer. 2019;7:306. [PMID: 31730012 DOI: 10.1186/s40425-019-0805-8] [Cited by in Crossref: 351] [Cited by in F6Publishing: 381] [Article Influence: 87.8] [Reference Citation Analysis]
185 Aso M, Toi Y, Sugisaka J, Aiba T, Kawana S, Saito R, Ogasawara T, Tsurumi K, Ono K, Shimizu H, Domeki Y, Terayama K, Kawashima Y, Nakamura A, Yamanda S, Kimura Y, Honda Y, Sugawara S. Association Between Skin Reaction and Clinical Benefit in Patients Treated with Anti-Programmed Cell Death 1 Monotherapy for Advanced Non-Small Cell Lung Cancer. Oncologist 2020;25:e536-44. [PMID: 32162801 DOI: 10.1634/theoncologist.2019-0550] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 5.0] [Reference Citation Analysis]
186 Dupont R, Bérard E, Puisset F, Comont T, Delord JP, Guimbaud R, Meyer N, Mazieres J, Alric L. The prognostic impact of immune-related adverse events during anti-PD1 treatment in melanoma and non-small-cell lung cancer: a real-life retrospective study. Oncoimmunology 2020;9:1682383. [PMID: 32002292 DOI: 10.1080/2162402X.2019.1682383] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 5.5] [Reference Citation Analysis]
187 Fukihara J, Sakamoto K, Koyama J, Ito T, Iwano S, Morise M, Ogawa M, Kondoh Y, Kimura T, Hashimoto N, Hasegawa Y. Prognostic Impact and Risk Factors of Immune-Related Pneumonitis in Patients With Non–Small-Cell Lung Cancer Who Received Programmed Death 1 Inhibitors. Clinical Lung Cancer 2019;20:442-450.e4. [DOI: 10.1016/j.cllc.2019.07.006] [Cited by in Crossref: 47] [Cited by in F6Publishing: 51] [Article Influence: 11.8] [Reference Citation Analysis]
188 Masuda K, Shoji H, Nagashima K, Yamamoto S, Ishikawa M, Imazeki H, Aoki M, Miyamoto T, Hirano H, Honma Y, Iwasa S, Okita N, Takashima A, Kato K, Boku N. Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab. BMC Cancer. 2019;19:974. [PMID: 31638948 DOI: 10.1186/s12885-019-6150-y] [Cited by in Crossref: 70] [Cited by in F6Publishing: 78] [Article Influence: 17.5] [Reference Citation Analysis]
189 Kus T, Aktas G. Durable response after interruption of nivolumab in patients with metastatic renal cell carcinoma: Is renal toxicity a marker to predict the benefit of nivolumab? J Oncol Pharm Pract 2020;26:1000-4. [PMID: 31594517 DOI: 10.1177/1078155219877923] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
190 Eun Y, Kim IY, Sun JM, Lee J, Cha HS, Koh EM, Kim H, Lee J. Risk factors for immune-related adverse events associated with anti-PD-1 pembrolizumab. Sci Rep 2019;9:14039. [PMID: 31575933 DOI: 10.1038/s41598-019-50574-6] [Cited by in Crossref: 68] [Cited by in F6Publishing: 73] [Article Influence: 17.0] [Reference Citation Analysis]
191 Okamoto I, Sato H, Kondo T, Koyama N, Fushimi C, Okada T, Miura K, Matsuki T, Yamashita T, Omura G, Tsukahara K. Efficacy and safety of nivolumab in 100 patients with recurrent or metastatic head and neck cancer - a retrospective multicentre study. Acta Otolaryngol 2019;139:918-25. [PMID: 31460818 DOI: 10.1080/00016489.2019.1648867] [Cited by in Crossref: 34] [Cited by in F6Publishing: 27] [Article Influence: 8.5] [Reference Citation Analysis]
192 Petrelli F, Grizzi G, Ghidini M, Ghidini A, Ratti M, Panni S, Cabiddu M, Ghilardi M, Borgonovo K, Parati MC, Tomasello G, Barni S, Berruti A, Brighenti M. Immune-related Adverse Events and Survival in Solid Tumors Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. Journal of Immunotherapy 2020;43:1-7. [DOI: 10.1097/cji.0000000000000300] [Cited by in Crossref: 40] [Cited by in F6Publishing: 43] [Article Influence: 10.0] [Reference Citation Analysis]
193 Anderson R, Theron AJ, Rapoport BL. Immunopathogenesis of Immune Checkpoint Inhibitor-Related Adverse Events: Roles of the Intestinal Microbiome and Th17 Cells. Front Immunol 2019;10:2254. [PMID: 31616428 DOI: 10.3389/fimmu.2019.02254] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 9.3] [Reference Citation Analysis]
194 Hayashi H, Nakagawa K. Combination therapy with PD-1 or PD-L1 inhibitors for cancer. Int J Clin Oncol. 2020;25:818-830. [PMID: 31549270 DOI: 10.1007/s10147-019-01548-1] [Cited by in Crossref: 51] [Cited by in F6Publishing: 56] [Article Influence: 12.8] [Reference Citation Analysis]
195 Braaten TJ, Brahmer JR, Forde PM, Le D, Lipson EJ, Naidoo J, Schollenberger M, Zheng L, Bingham CO, Shah AA, Cappelli LC. Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation. Ann Rheum Dis 2020;79:332-8. [PMID: 31540935 DOI: 10.1136/annrheumdis-2019-216109] [Cited by in Crossref: 97] [Cited by in F6Publishing: 102] [Article Influence: 24.3] [Reference Citation Analysis]
196 Takada K, Toyokawa G, Yoneshima Y, Tanaka K, Okamoto I, Shimokawa M, Wakasu S, Haro A, Osoegawa A, Tagawa T, Oda Y, Nakanishi Y, Mori M. 18F-FDG uptake in PET/CT is a potential predictive biomarker of response to anti-PD-1 antibody therapy in non-small cell lung cancer. Sci Rep 2019;9:13362. [PMID: 31527660 DOI: 10.1038/s41598-019-50079-2] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 7.3] [Reference Citation Analysis]
197 Ohba T, Takamori S, Toyozawa R, Nosaki K, Umeyama Y, Haratake N, Miura N, Yamaguchi M, Taguchi K, Seto T, Shimokawa M, Takenoyama M. Prognostic impact of the Controlling Nutritional Status score in patients with non-small cell lung cancer treated with pembrolizumab. J Thorac Dis 2019;11:3757-68. [PMID: 31656648 DOI: 10.21037/jtd.2019.09.29] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 4.5] [Reference Citation Analysis]
198 Cortellini A, Buti S, Agostinelli V, Bersanelli M. A systematic review on the emerging association between the occurrence of immune-related adverse events and clinical outcomes with checkpoint inhibitors in advanced cancer patients. Seminars in Oncology 2019;46:362-71. [DOI: 10.1053/j.seminoncol.2019.10.003] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 7.3] [Reference Citation Analysis]
199 Horinouchi H, Nishio M, Hida T, Nakagawa K, Sakai H, Nogami N, Atagi S, Takahashi T, Saka H, Takenoyama M, Katakami N, Tanaka H, Takeda K, Satouchi M, Isobe H, Maemondo M, Goto K, Hirashima T, Minato K, Sumiyoshi N, Tamura T. Three-year follow-up results from phase II studies of nivolumab in Japanese patients with previously treated advanced non-small cell lung cancer: Pooled analysis of ONO-4538-05 and ONO-4538-06 studies. Cancer Med 2019;8:5183-93. [PMID: 31353840 DOI: 10.1002/cam4.2411] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
200 Greally M, Chou JF, Chatila WK, Margolis M, Capanu M, Hechtman JF, Tuvy Y, Kundra R, Daian F, Ladanyi M, Kelsen DP, Ilson DH, Berger MF, Tang LH, Solit DB, Diaz LA Jr, Schultz N, Janjigian YY, Ku GY. Clinical and Molecular Predictors of Response to Immune Checkpoint Inhibitors in Patients with Advanced Esophagogastric Cancer. Clin Cancer Res 2019;25:6160-9. [PMID: 31337644 DOI: 10.1158/1078-0432.CCR-18-3603] [Cited by in Crossref: 51] [Cited by in F6Publishing: 54] [Article Influence: 12.8] [Reference Citation Analysis]
201 Bjørnhart B, Hansen KH, Jørgensen TL, Herrstedt J, Schytte T. Efficacy and safety of immune checkpoint inhibitors in a Danish real life non-small cell lung cancer population: a retrospective cohort study. Acta Oncol 2019;58:953-61. [PMID: 31081424 DOI: 10.1080/0284186X.2019.1615636] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 7.0] [Reference Citation Analysis]
202 Cortellini A, Chiari R, Ricciuti B, Metro G, Perrone F, Tiseo M, Bersanelli M, Bordi P, Santini D, Giusti R, Grassadonia A, Di Marino P, Tinari N, De Tursi M, Zoratto F, Veltri E, Malorgio F, Garufi C, Russano M, Anesi C, Zeppola T, Filetti M, Marchetti P, Berardi R, Rinaldi S, Tudini M, Silva RR, Pireddu A, Atzori F, Iacono D, Migliorino MR, Porzio G, Cannita K, Ficorella C, Buti S. Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients. Clinical Lung Cancer 2019;20:237-247.e1. [DOI: 10.1016/j.cllc.2019.02.006] [Cited by in Crossref: 76] [Cited by in F6Publishing: 75] [Article Influence: 19.0] [Reference Citation Analysis]
203 Bisschop C, Wind TT, Blank CU, Koornstra RH, Kapiteijn E, Van den Eertwegh AJ, De Groot JWB, Jalving M, Hospers GA. Association Between Pembrolizumab-related Adverse Events and Treatment Outcome in Advanced Melanoma: Results From the Dutch Expanded Access Program. Journal of Immunotherapy 2019;42:208-14. [DOI: 10.1097/cji.0000000000000271] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
204 Sidiropoulou P, Sgontzou T, Kostara I, Sgouros D, Theologi B, Zouridaki E, Kontochristopoulos G, Rigopoulos D, J Stratigos A. Nivolumab in non-small cell lung cancer: A novel case of an erythema annulare centrifugum-like eruption. JAAD Case Rep 2019;5:572-5. [PMID: 31312704 DOI: 10.1016/j.jdcr.2019.04.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
205 Miura S, Isogai S, Yoshino M, Baba J, Kajiwara T, Koyama K, Takenouchi T, Tani N, Tanaka H. Management of Adverse Events Induced by Immune Checkpoint Inhibitors in Lung Cancer Treatment. JJLC 2019;59:231-237. [DOI: 10.2482/haigan.59.231] [Reference Citation Analysis]
206 Tokuyasu H, Ishikawa S, Sakai H, Ikeuchi T, Miura H. Single pembrolizumab treatment causing profound durable response in a patient with pulmonary pleomorphic carcinoma. Respir Med Case Rep. 2019;28:100879. [PMID: 31249776 DOI: 10.1016/j.rmcr.2019.100879] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
207 Akano Y, Kuribayashi K, Funaguchi N, Koda Y, Fujimoto E, Mikami K, Minami T, Takahashi R, Yokoi T, Kijima T. Analysis of Pleiotropic Effects of Nivolumab in Pretreated Advanced or Recurrent Non-small Cell Lung Cancer Cases. In Vivo 2019;33:507-14. [PMID: 30804134 DOI: 10.21873/invivo.11503] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
208 Dhenin A, Samartzi V, Lejeune S, Seront E. Cascade of immunologic adverse events related to pembrolizumab treatment. BMJ Case Rep. 2019;12. [PMID: 31167767 DOI: 10.1136/bcr-2018-229149] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
209 Remon J, Esteller L, Taus Á. Nivolumab plus ipilimumab combination therapy for the first-line treatment NSCLC: evidence to date. Cancer Manag Res 2019;11:4893-904. [PMID: 31213908 DOI: 10.2147/CMAR.S164935] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
210 Sato R, Imamura K, Sakata S, Ikeda T, Horio Y, Iyama S, Akaike K, Hamada S, Jodai T, Nakashima K, Ishizuka S, Sato N, Saruwatari K, Saeki S, Tomita Y, Sakagami T. Disorder of Coagulation-Fibrinolysis System: An Emerging Toxicity of Anti-PD-1/PD-L1 Monoclonal Antibodies. J Clin Med 2019;8:E762. [PMID: 31146442 DOI: 10.3390/jcm8060762] [Cited by in Crossref: 35] [Cited by in F6Publishing: 37] [Article Influence: 8.8] [Reference Citation Analysis]
211 Nakamura Y. Biomarkers for Immune Checkpoint Inhibitor-Mediated Tumor Response and Adverse Events. Front Med (Lausanne) 2019;6:119. [PMID: 31192215 DOI: 10.3389/fmed.2019.00119] [Cited by in Crossref: 95] [Cited by in F6Publishing: 100] [Article Influence: 23.8] [Reference Citation Analysis]
212 Ma K, Jin Q, Wang M, Li X, Zhang Y. Research progress and clinical application of predictive biomarker for immune checkpoint inhibitors. Expert Rev Mol Diagn 2019;19:517-29. [PMID: 31079502 DOI: 10.1080/14737159.2019.1617702] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
213 Ksienski D, Wai ES, Croteau N, Freeman AT, Chan A, Fiorino L, Brooks EG, Poonja Z, Fenton D, Geller G, Irons S, Lesperance M. Pembrolizumab for advanced nonsmall cell lung cancer: Efficacy and safety in everyday clinical practice. Lung Cancer 2019;133:110-6. [PMID: 31200816 DOI: 10.1016/j.lungcan.2019.05.005] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 5.3] [Reference Citation Analysis]
214 Chang LS, Barroso-Sousa R, Tolaney SM, Hodi FS, Kaiser UB, Min L. Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints. Endocr Rev. 2019;40:17-65. [PMID: 30184160 DOI: 10.1210/er.2018-00006] [Cited by in Crossref: 218] [Cited by in F6Publishing: 235] [Article Influence: 54.5] [Reference Citation Analysis]
215 Liang H, Liu Z, Cai X, Pan Z, Chen D, Li C, Chen Y, He J, Liang W. PD-(L)1 inhibitors vs. chemotherapy vs. their combination in front-line treatment for NSCLC: An indirect comparison. Int J Cancer 2019;145:3011-21. [PMID: 31018251 DOI: 10.1002/ijc.32366] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
216 Afzal MZ, Dragnev K, Sarwar T, Shirai K. Clinical outcomes in non-small-cell lung cancer patients receiving concurrent metformin and immune checkpoint inhibitors. Lung Cancer Manag 2019;8:LMT11. [PMID: 31645894 DOI: 10.2217/lmt-2018-0016] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 9.5] [Reference Citation Analysis]
217 Chrétien S, Zerdes I, Bergh J, Matikas A, Foukakis T. Beyond PD-1/PD-L1 Inhibition: What the Future Holds for Breast Cancer Immunotherapy. Cancers (Basel) 2019;11:E628. [PMID: 31060337 DOI: 10.3390/cancers11050628] [Cited by in Crossref: 39] [Cited by in F6Publishing: 40] [Article Influence: 9.8] [Reference Citation Analysis]
218 Koyama J, Horiike A, Yoshizawa T, Dotsu Y, Ariyasu R, Saiki M, Sonoda T, Uchibori K, Nishikawa S, Kitazono S, Yanagitani N, Ninomiya H, Ishikawa Y, Nishio M. Correlation between thyroid transcription factor-1 expression, immune-related thyroid dysfunction, and efficacy of anti-programmed cell death protein-1 treatment in non-small cell lung cancer. J Thorac Dis 2019;11:1919-28. [PMID: 31285885 DOI: 10.21037/jtd.2019.04.102] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
219 Duma N, Abdel-Ghani A, Yadav S, Hoversten KP, Reed CT, Sitek AN, Enninga EAL, Paludo J, Aguilera JV, Leventakos K, Lou Y, Kottschade LA, Dong H, Mansfield AS, Manochakian R, Adjei AA, Dronca RS. Sex Differences in Tolerability to Anti-Programmed Cell Death Protein 1 Therapy in Patients with Metastatic Melanoma and Non-Small Cell Lung Cancer: Are We All Equal? Oncologist 2019;24:e1148-55. [PMID: 31036771 DOI: 10.1634/theoncologist.2019-0094] [Cited by in Crossref: 49] [Cited by in F6Publishing: 55] [Article Influence: 12.3] [Reference Citation Analysis]
220 Beck TN, Kudinov AE, Dulaimi E, Boumber Y. Case report: reinitiating pembrolizumab treatment after small bowel perforation. BMC Cancer 2019;19:379. [PMID: 31018834 DOI: 10.1186/s12885-019-5577-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
221 Remon J, Reguart N, Auclin E, Besse B. Immune-Related Adverse Events and Outcomes in Patients with Advanced Non-Small Cell Lung Cancer: A Predictive Marker of Efficacy? J Thorac Oncol 2019;14:963-7. [PMID: 31027971 DOI: 10.1016/j.jtho.2019.02.031] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
222 Verzoni E, Cartenì G, Cortesi E, Giannarelli D, De Giglio A, Sabbatini R, Buti S, Rossetti S, Cognetti F, Rastelli F, Sobrero A, Turci D, Sternberg CN, Porta C, Cappuzzo F, Tortora G, Tassinari D, Panni S, Pazzola A, Surico G, Raimondi A, De Giorgi U, Procopio G; Italian Nivolumab Renal Cell Cancer Early Access Program group. Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program. J Immunother Cancer 2019;7:99. [PMID: 30944023 DOI: 10.1186/s40425-019-0579-z] [Cited by in Crossref: 79] [Cited by in F6Publishing: 85] [Article Influence: 19.8] [Reference Citation Analysis]
223 Honjo O, Kubo T, Sugaya F, Nishizaka T, Kato K, Hirohashi Y, Takahashi H, Torigoe T. Severe cytokine release syndrome resulting in purpura fulminans despite successful response to nivolumab therapy in a patient with pleomorphic carcinoma of the lung: a case report. J Immunother Cancer 2019;7:97. [PMID: 30944043 DOI: 10.1186/s40425-019-0582-4] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 8.3] [Reference Citation Analysis]
224 Kyriazoglou A, Liontos M, Papadopoulos C, Bilali A, Kostouros E, Pagoni S, Doumas K, Dimopoulos MA, Bamias A. Guillain-Barré Syndrome Related to Nivolumab: Case Report of a Patient With Urothelial Cancer and Review of the Literature. Clinical Genitourinary Cancer 2019;17:e360-4. [DOI: 10.1016/j.clgc.2018.11.022] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
225 Petrelli F, Ghidini M, Costanzo A, Rampulla V, Varricchio A, Tomasello G. Surrogate endpoints in immunotherapy trials for solid tumors. Ann Transl Med 2019;7:154. [PMID: 31157275 DOI: 10.21037/atm.2019.03.20] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
226 Ahn BC, Pyo KH, Xin CF, Jung D, Shim HS, Lee CY, Park SY, Yoon HI, Hong MH, Cho BC, Kim HR. Comprehensive analysis of the characteristics and treatment outcomes of patients with non-small cell lung cancer treated with anti-PD-1 therapy in real-world practice. J Cancer Res Clin Oncol 2019;145:1613-23. [PMID: 30911841 DOI: 10.1007/s00432-019-02899-y] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 10.8] [Reference Citation Analysis]
227 Oyanagi J, Koh Y, Sato K, Mori K, Teraoka S, Akamatsu H, Kanai K, Hayata A, Tokudome N, Akamatsu K, Nakanishi M, Ueda H, Yamamoto N. Predictive value of serum protein levels in patients with advanced non-small cell lung cancer treated with nivolumab. Lung Cancer 2019;132:107-13. [PMID: 31097082 DOI: 10.1016/j.lungcan.2019.03.020] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 7.0] [Reference Citation Analysis]
228 Hofman P. Is the onset of adverse effects of immunotherapy always bad news for the patients…?-certainly not! Ann Transl Med 2019;7:S5. [PMID: 31032286 DOI: 10.21037/atm.2019.01.14] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
229 Ozawa Y, Amano Y, Kanata K, Hasegwa H, Matsui T, Kakutani T, Koyauchi T, Tanahashi M, Niwa H, Yokomura K, Suda T. Impact of early inflammatory cytokine elevation after commencement of PD-1 inhibitors to predict efficacy in patients with non-small cell lung cancer. Med Oncol 2019;36:33. [PMID: 30825015 DOI: 10.1007/s12032-019-1255-3] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 7.3] [Reference Citation Analysis]
230 Okawa S, Kayatani H, Fujiwara K, Ozeki T, Takada K, Iwamoto Y, Minami D, Sato K, Shibayama T. Pembrolizumab-induced Autoimmune Hemolytic Anemia and Hemophagocytic Lymphohistiocytosis in Non-small Cell Lung Cancer. Intern Med 2019;58:699-702. [PMID: 30828042 DOI: 10.2169/internalmedicine.1001-18] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 5.3] [Reference Citation Analysis]
231 Cortellini A, Bersanelli M, Buti S, Cannita K, Santini D, Perrone F, Giusti R, Tiseo M, Michiara M, Di Marino P, Tinari N, De Tursi M, Zoratto F, Veltri E, Marconcini R, Malorgio F, Russano M, Anesi C, Zeppola T, Filetti M, Marchetti P, Botticelli A, Antonini Cappellini GC, De Galitiis F, Vitale MG, Rastelli F, Pergolesi F, Berardi R, Rinaldi S, Tudini M, Silva RR, Pireddu A, Atzori F, Chiari R, Ricciuti B, De Giglio A, Iacono D, Gelibter A, Occhipinti MA, Parisi A, Porzio G, Fargnoli MC, Ascierto PA, Ficorella C, Natoli C. A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable. J Immunother Cancer 2019;7:57. [PMID: 30813970 DOI: 10.1186/s40425-019-0527-y] [Cited by in Crossref: 176] [Cited by in F6Publishing: 185] [Article Influence: 44.0] [Reference Citation Analysis]
232 Plaçais L, Hau E, Delyon J, Azoulay E, Gautier JF, Lebbé C, Baroudjian B; PATIO Group. Refractory hypotension with fever revealing checkpoint inhibitor-induced hypophysitis. Melanoma Res 2019;29:205-7. [PMID: 30801428 DOI: 10.1097/CMR.0000000000000517] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
233 Sawada K, Shonaka T, Nishikawa Y, Hasegawa K, Hayashi H, Hasebe T, Nakajima S, Ikuta K, Fujiya M, Furukawa H, Okumura T. Successful Treatment of Nivolumab-related Cholangitis with Prednisolone: A Case Report and Review of the Literature. Intern Med. 2019;58:1747-1752. [PMID: 30799364 DOI: 10.2169/internalmedicine.2330-18] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
234 Nakamura A, Aiba T, Kawana S, Saito R, Toi Y, Sugawara S. A Case of Pseudoprogression in Lung Adenocarcinoma Treated with Nivolumab. JJLC 2019;59:60-65. [DOI: 10.2482/haigan.59.60] [Reference Citation Analysis]
235 Rogado J, Sánchez-Torres JM, Romero-Laorden N, Ballesteros AI, Pacheco-Barcia V, Ramos-Leví A, Arranz R, Lorenzo A, Gullón P, Donnay O, Adrados M, Costas P, Aspa J, Alfranca A, Mondéjar R, Colomer R. Immune-related adverse events predict the therapeutic efficacy of anti-PD-1 antibodies in cancer patients. Eur J Cancer 2019;109:21-7. [PMID: 30682533 DOI: 10.1016/j.ejca.2018.10.014] [Cited by in Crossref: 132] [Cited by in F6Publishing: 138] [Article Influence: 33.0] [Reference Citation Analysis]
236 Andrews SC, Davies M. The Impact and Toxicity of Checkpoint Inhibitors in Management of Lung Cancer. Targeted Therapies in Lung Cancer: Management Strategies for Nurses and Practitioners 2019. [DOI: 10.1007/978-3-030-16550-5_7] [Reference Citation Analysis]
237 Ksienski D, Wai ES, Croteau N, Fiorino L, Brooks E, Poonja Z, Fenton D, Geller G, Glick D, Lesperance M. Efficacy of Nivolumab and Pembrolizumab in Patients With Advanced Non–Small-Cell Lung Cancer Needing Treatment Interruption Because of Adverse Events: A Retrospective Multicenter Analysis. Clinical Lung Cancer 2019;20:e97-e106. [DOI: 10.1016/j.cllc.2018.09.005] [Cited by in Crossref: 50] [Cited by in F6Publishing: 53] [Article Influence: 12.5] [Reference Citation Analysis]
238 Saijo T, Tanaka A, Ito T, Ikeda N. A Case of Nivolumab-induced Severe Neutropenia with Stomatitis, Enteritis and Liver Dysfunction. JJLC 2018;58:996-1000. [DOI: 10.2482/haigan.58.996] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
239 Okada N, Kawazoe H, Takechi K, Matsudate Y, Utsunomiya R, Zamami Y, Goda M, Imanishi M, Chuma M, Hidaka N, Sayama K, Kubo Y, Tanaka A, Ishizawa K. Association Between Immune-Related Adverse Events and Clinical Efficacy in Patients with Melanoma Treated With Nivolumab: A Multicenter Retrospective Study. Clin Ther 2019;41:59-67. [PMID: 30528047 DOI: 10.1016/j.clinthera.2018.11.004] [Cited by in Crossref: 65] [Cited by in F6Publishing: 72] [Article Influence: 13.0] [Reference Citation Analysis]
240 Ricciuti B, Genova C, De Giglio A, Bassanelli M, Dal Bello MG, Metro G, Brambilla M, Baglivo S, Grossi F, Chiari R. Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis. J Cancer Res Clin Oncol 2019;145:479-85. [DOI: 10.1007/s00432-018-2805-3] [Cited by in Crossref: 171] [Cited by in F6Publishing: 150] [Article Influence: 34.2] [Reference Citation Analysis]
241 Nakamura K, Okubo K, Takahashi T, Mitsumori K, Ishigaki T, Ohnishi H. Radiation recall pneumonitis induced by nivolumab in a patient with renal cell carcinoma. IJU Case Rep 2019;2:30-3. [PMID: 32743367 DOI: 10.1002/iju5.12032] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
242 Spagnuolo A, Gridelli C. "Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer": is there a substantial difference or not? J Thorac Dis 2018;10:S4065-8. [PMID: 30631556 DOI: 10.21037/jtd.2018.09.83] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
243 Tozuka T, Sugano T, Noro R, Takano N, Hisakane K, Takahashi S, Tanaka T, Kashiwada T, Takeuchi S, Kunugi S, Minegishi Y, Saito Y, Kubota K, Seike M, Gemma A. Pembrolizumab-induced agranulocytosis in a pulmonary pleomorphic carcinoma patient who developed interstitial lung disease and ocular myasthenia gravis. Oxf Med Case Reports 2018;2018:omy094. [PMID: 30364514 DOI: 10.1093/omcr/omy094] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
244 Grangeon M, Tomasini P, Chaleat S, Jeanson A, Souquet-Bressand M, Khobta N, Bermudez J, Trigui Y, Greillier L, Blanchon M, Boucekine M, Mascaux C, Barlesi F. Association Between Immune-related Adverse Events and Efficacy of Immune Checkpoint Inhibitors in Non-small-cell Lung Cancer. Clin Lung Cancer. 2019;20:201-207. [PMID: 30442524 DOI: 10.1016/j.cllc.2018.10.002] [Cited by in Crossref: 80] [Cited by in F6Publishing: 90] [Article Influence: 16.0] [Reference Citation Analysis]
245 Yamaura T, Suzuki H. Pseudoprogression and Rapid Response to Pembrolizumab in a Patient with Advanced Lung Adenocarcinoma with Loss of Epidermal Growth Factor Receptor Gene Mutation after Tyrosine Kinase Inhibitor Therapy. Journal of Thoracic Oncology 2018;13:e209-10. [DOI: 10.1016/j.jtho.2018.05.021] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
246 Owen DH, Wei L, Bertino EM, Edd T, Villalona-Calero MA, He K, Shields PG, Carbone DP, Otterson GA. Incidence, Risk Factors, and Effect on Survival of Immune-related Adverse Events in Patients With Non-Small-cell Lung Cancer. Clin Lung Cancer 2018;19:e893-900. [PMID: 30197259 DOI: 10.1016/j.cllc.2018.08.008] [Cited by in Crossref: 62] [Cited by in F6Publishing: 68] [Article Influence: 12.4] [Reference Citation Analysis]
247 Sekine K, Kanda S, Goto Y, Horinouchi H, Fujiwara Y, Yamamoto N, Motoi N, Ohe Y. Change in the lymphocyte-to-monocyte ratio is an early surrogate marker of the efficacy of nivolumab monotherapy in advanced non-small-cell lung cancer. Lung Cancer 2018;124:179-88. [PMID: 30268458 DOI: 10.1016/j.lungcan.2018.08.012] [Cited by in Crossref: 36] [Cited by in F6Publishing: 41] [Article Influence: 7.2] [Reference Citation Analysis]
248 Tanaka K, Yanagihara T, Ikematsu Y, Inoue H, Ota K, Kashiwagi E, Suzuki K, Hamada N, Takeuchi A, Tatsugami K, Eto M, Ijichi K, Oda Y, Otsubo K, Yoneshima Y, Iwama E, Nakanishi Y, Okamoto I. Detection of identical T cell clones in peritumoral pleural effusion and pneumonitis lesions in a cancer patient during immune-checkpoint blockade. Oncotarget 2018;9:30587-93. [PMID: 30093971 DOI: 10.18632/oncotarget.25743] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
249 Hamada S, Fuseya Y, Tsukino M. Pembrolizumab-Induced Rhabdomyolysis With Myositis in a Patient With Lung Adenocarcinoma. Archivos de Bronconeumología (English Edition) 2018;54:346-8. [DOI: 10.1016/j.arbr.2018.01.026] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
250 Hamada S, Fuseya Y, Tsukino M. Pembrolizumab-Induced Rhabdomyolysis With Myositis in a Patient With Lung Adenocarcinoma. Archivos de Bronconeumología 2018;54:346-8. [DOI: 10.1016/j.arbres.2018.01.026] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
251 Rzepecki AK, Cheng H, McLellan BN. Cutaneous toxicity as a predictive biomarker for clinical outcome in patients receiving anticancer therapy. J Am Acad Dermatol 2018;79:545-55. [PMID: 29733938 DOI: 10.1016/j.jaad.2018.04.046] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 5.0] [Reference Citation Analysis]
252 Tay R, Prelaj A, Califano R. Immune checkpoint blockade for advanced non-small cell lung cancer: challenging clinical scenarios. J Thorac Dis 2018;10:S1494-502. [PMID: 29951301 DOI: 10.21037/jtd.2018.01.80] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
253 Remon J, Mezquita L, Corral J, Vilariño N, Reguart N. Immune-related adverse events with immune checkpoint inhibitors in thoracic malignancies: focusing on non-small cell lung cancer patients. J Thorac Dis 2018;10:S1516-33. [PMID: 29951303 DOI: 10.21037/jtd.2017.12.52] [Cited by in Crossref: 39] [Cited by in F6Publishing: 45] [Article Influence: 7.8] [Reference Citation Analysis]
254 Sosa A, Lopez Cadena E, Simon Olive C, Karachaliou N, Rosell R. Clinical assessment of immune-related adverse events. Ther Adv Med Oncol 2018;10:1758835918764628. [PMID: 29623110 DOI: 10.1177/1758835918764628] [Cited by in Crossref: 72] [Cited by in F6Publishing: 81] [Article Influence: 14.4] [Reference Citation Analysis]
255 Fujimoto D, Yoshioka H, Kataoka Y, Morimoto T, Kim YH, Tomii K, Ishida T, Hirabayashi M, Hara S, Ishitoko M, Fukuda Y, Hwang MH, Sakai N, Fukui M, Nakaji H, Morita M, Mio T, Yasuda T, Sugita T, Hirai T. Efficacy and safety of nivolumab in previously treated patients with non-small cell lung cancer: A multicenter retrospective cohort study. Lung Cancer 2018;119:14-20. [PMID: 29656747 DOI: 10.1016/j.lungcan.2018.02.017] [Cited by in Crossref: 88] [Cited by in F6Publishing: 94] [Article Influence: 17.6] [Reference Citation Analysis]
256 Remon J, Vilariño N, Reguart N. Immune checkpoint inhibitors in non-small cell lung cancer (NSCLC): Approaches on special subgroups and unresolved burning questions. Cancer Treat Rev 2018;64:21-9. [PMID: 29454155 DOI: 10.1016/j.ctrv.2018.02.002] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 6.2] [Reference Citation Analysis]
257 Sato K, Akamatsu H, Murakami E, Sasaki S, Kanai K, Hayata A, Tokudome N, Akamatsu K, Koh Y, Ueda H, Nakanishi M, Yamamoto N. Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab. Lung Cancer 2018;115:71-4. [DOI: 10.1016/j.lungcan.2017.11.019] [Cited by in Crossref: 233] [Cited by in F6Publishing: 249] [Article Influence: 46.6] [Reference Citation Analysis]
258 Kataoka Y, Hirano K, Narabayashi T, Hara S, Fujimoto D, Tanaka T, Ebi N, Tomii K, Yoshioka H. Concordance between the response evaluation criteria in solid tumors version 1.1 and the immune-related response criteria in patients with non-small cell lung cancer treated with nivolumab: a multicenter retrospective cohort study. Cancer Chemother Pharmacol 2018;81:333-7. [PMID: 29230503 DOI: 10.1007/s00280-017-3498-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]